People

Sri Mulyani Indrawati is one of Indonesia's longest-serving and first female minister of finance, serving under three democratically elected presidents. Sri Mulyani led the country through major crises such as the global financial crisis and COVID-19 pandemic, while restoring fiscal discipline, achieving macroeconomic stability, restoring growth and reducing poverty - while elevating Indonesia's sovereign credit rating to investment grade. Sri Mulyani reformed and modernized the Ministry of Finance, strengthened public financial management–fighting corruption and building good governance and positioned Indonesia as a global leader in sustainable finance, including issuing the first sovereign Green Sukuk by an emerging economy. Internationally, Sri Mulyani has held senior leadership roles at the World Bank and the IMF and has advanced global cooperation through ASEAN and the G20. Sri Mulyani has received numerous international honors, including Best Minister in the World and recognition on Forbes' list of the World's 100 Most Powerful Women.

Dr. Helene D. Gayle served as president of Spelman College, the No. 1 historically Black college or university in the country. A global leader in the education of women of African descent, Spelman College is dedicated to academic excellence in the liberal arts and sciences and the intellectual, creative, ethical, and leadership development of its students. Previously, Helene was president and CEO of The Chicago Community Trust, one of the nation’s oldest and largest community foundations. Under her leadership, the Trust adopted a new strategic focus on closing the racial and ethnic wealth gap in the Chicago region. An internationally recognized expert on health and humanitarian issues, as well as global and domestic economic development, Helene spent nearly a decade as president and CEO of the international humanitarian organization CARE. Prior to that, Helene served as the director of the HIV, TB, and Reproductive Health program at the Gates Foundation. She began her career at the Centers for Disease Control and Prevention, where she spent 20 years focusing primarily on HIV/AIDS prevention and global health. Helene serves on several public company and nonprofit boards, including the Coca-Cola Company, Organon, Palo Alto Networks, Brookings Institution, Center for Strategic and International Studies, New America, and ONE. She is a member of the American Academy of Arts and Sciences, Council on Foreign Relations, American Public Health Association, National Academy of Medicine, National Medical Association, and American Academy of Pediatrics. A recipient of numerous awards, Helene has authored articles on global and domestic public health issues, poverty alleviation, gender equality, and wealth inequity. She has received 18 honorary degrees and holds faculty appointments at the University of Washington and Emory University. Helene earned a B.A. in psychology from Barnard College, an M.D. from the University of Pennsylvania, and an M.P.H. from Johns Hopkins University.

Ashish Dhawan is the founder and CEO of the Convergence Foundation (TCF), which is focused on accelerating India’s economic growth and development. He is also the chairperson of Ashoka University, a leading liberal arts university in India, and Central Square Foundation, a nonprofit foundation working to improve the quality of education for all children in India. TCF incubates nonprofits focused on creating system-wide impact in the areas of economic growth, equality of opportunity, and sustainability. Its current portfolio includes organizations working on jobs and investment, rule of law, governance and state capacity, economic empowerment of women, science and technology, air pollution, unlocking philanthropic capital, and improving the effectiveness of nonprofits. Before his second career as a philanthropist, Ashish was among India’s most successful private equity investors. He founded and ran ChrysCapital, the country’s leading private equity firm. Ashish graduated from Yale University and received his M.B.A. from Harvard Business School. He is also on the India Advisory Board of Harvard and a member of Yale’s Development Council. It’s a tremendous opportunity to work to improve the human condition across the world, nothing can be more important than that. - Ashish Dhawan Board Member Gates Foundation

Dr. Anita Zaidi oversees the foundation’s efforts to advance gender equality by including gender in all of the foundation’s global work. She seeks to ensure that women and girls in sub-Saharan Africa and South Asia can enjoy good health, make their own choices, earn their own money, and be leaders in their societies. The mission of the Gender Equality Division is a world in which everyone, everywhere, can thrive. Anita joined the foundation in 2014 to lead a team focused on vaccine development for people in the poorest parts of the world, disease surveillance to identify and address causes of death in children in the most underserved areas, and to significantly reduce the adverse consequences of diarrheal and enteric infections on children’s health in low and middle-income countries. She served as director of the foundation’s Enteric and Diarrheal Diseases team and Vaccine Development and Surveillance team until November 2022. In those roles, Anita led strategies resulting in the development and deployment of many lifesaving and disease-preventing vaccines, including rotavirus vaccines, typhoid conjugate vaccines, cholera vaccines, and novel oral polio vaccines. She also championed innovative work on behalf of low-income women and children, including the creation of the foundation’s Maternal, Newborn & Child Health upstream innovations strategy. She has led the Gender Equality Division since November 2020. Previously, Anita served as chair of the Department of Pediatrics and Child Health at the Aga Khan University (AKU) in Karachi, Pakistan, where she worked to reduce child mortality through the prevention and treatment of newborn illnesses and vaccine-preventable diseases. Anita earned a medical degree at AKU and completed further training at Duke University (pediatrics and microbiology), Boston Children’s Hospital, Harvard Medical School (pediatric infectious diseases), and the Harvard School of Public Health. She has published more than 200 research papers on vaccine-preventable diseases and newborn infections in resource-limited settings. In 2013, Anita became the first recipient of the US$1 million Caplow Children’s Prize for her pioneering work on bringing health services and wraparound care to mothers and children in low-income communities in Karachi. In 2014, she was nominated as a physician of the year by Medscape. In 2021, she was elected to the U.S. National Academy of Medicine for her global leadership in pediatric infectious disease research and capacity development for improving newborn and child survival in low- and middle-income countries.

Trevor Mundel leads the foundation’s efforts to develop high-impact interventions against the leading causes of death and disability in developing countries. He manages the foundation’s disease-specific R&D investments in HIV, Tuberculosis, Malaria, Pneumonia, Enteric and Diarrheal Diseases, and Neglected Tropical Diseases. He also manages cross-cutting product development programs, including Discovery & Translational Sciences, Innovative Technology Solutions, Integrated Development, and Vaccine Development & Surveillance. This work relies on close collaboration with an international network of grantees and partners. Prior to joining the foundation in 2011, Trevor was global head of development with Novartis and previously was involved in clinical research at Pfizer and Parke-Davis. Born and raised in South Africa, Trevor earned his bachelor’s and medical degrees from the University of the Witwatersrand in Johannesburg. He also studied mathematics, logic, and philosophy as a Rhodes Scholar at Oxford University, and he earned a Ph.D. in mathematics at the University of Chicago.

Patrick leads the foundation’s efforts to ensure education works as a pathway to good jobs and upward mobility for far more Americans. Patrick joined the foundation in 2013 and has worked across several aspects of its U.S. education strategy, spanning K-12, pathways, and postsecondary education. His work has included partnering with institutions to redesign how they serve students, advancing new solutions and technologies, and strengthening the policy, communications, and data infrastructure that make lasting progress possible. Across these roles, Patrick has focused on how the different parts of the education continuum can work together to create more opportunities for students to thrive. Before joining the foundation, Patrick was a principal at Boston Consulting Group, where his work included supporting higher education institutions and K-12 systems through significant organizational and strategic change. Patrick holds an MBA from the Wharton School, a master's in educational leadership from the University of Pennsylvania, and a B.A. in Economics and Political Science from the University of North Carolina, where he was a Morehead Scholar.

Hari Menon leads the foundation's Global Growth & Opportunity Division, which includes the Agricultural Development, Digital Public Infrastructure, Global Education, Inclusive Financial Systems, Nutrition, and Water, Sanitation & Hygiene programs. These programs work to strengthen food security and improve incomes so millions of families can break free from poverty and more low-income countries in sub-Saharan Africa and South Asia can get on a path to prosperity. They support greater productivity on smallholder farms; expanded access to high-quality digital public infrastructure, including payment systems; improved foundational reading and math skills among children; development of large-scale food fortification systems; and delivery of innovative sanitation products and services. Before assuming his current role, Hari led the India office, overseeing the foundation's work in South and Southeast Asia spanning family health, nutrition, sanitation, digital financial inclusion, agriculture, and women's economic empowerment. These efforts, carried out in close collaboration with governments, local and global nonprofits, philanthropies, community groups, researchers, and the private sector, have contributed to progress toward India's national health and development goals and strengthened the foundation's partnerships in countries including Singapore, Indonesia, and Sri Lanka. Hari's earlier roles at the foundation included working on a range of public health efforts, particularly in maternal and child health and HIV prevention; leading policy, advocacy, and communications for programs in the Global Health, Global Development, and Global Growth & Opportunity divisions; and leading the foundation's policy work, government relations, and philanthropic partnerships in South and Southeast Asia. Hari has been at the foundation since 2004, with a brief stint (2011–2013) outside the organization as a strategic adviser to philanthropist Rohini Nilekani. Earlier in his career, Hari worked in the consumer goods and information technology sectors for companies including Colgate Palmolive and Infosys Technologies. Hari has a graduate degree in business management from XLRI – Xavier School of Management, Jamshedpur, and a bachelor's degree in mechanical engineering from the Faculty of Engineering and Technology, Jamia Millia Islamia, Delhi.

Kalpana Kochhar leads the foundation's work in international political and economic affairs, overseeing relationships with governments, intergovernmental organizations, advocates, and philanthropic partners worldwide. Kalpana previously served as director of the Development Policy and Finance team, a group of economists and development finance experts working to ensure that the foundation's global policy and advocacy work is informed by strong economic and financial analysis and insights, resonant with emerging trends, and connected to key decision-makers. Before joining the foundation in 2021, Kalpana spent 33 years at the International Monetary Fund (IMF), where her most recent position was director of the Human Resources Department. She also served as deputy director of the Asia and Pacific Department, working on programs and issues related to India, China, Korea, Japan, and several other Asian countries, and as deputy director of the Strategy, Policy, and Review Department, where she launched the IMF's work on gender and women's economic empowerment. From 2010 to 2012, she was seconded to the World Bank as its chief economist for the South Asia region. Kalpana's research interests and publications have focused on emerging markets, including India and China; jobs and inclusive growth; gender and inequality issues; structural reforms; and regional integration in South Asia. She has an M.A. and Ph.D. in economics from Brown University and an M.A. in economics from the Delhi School of Economics in India. She has a B.A in economics from Madras University in India.

Dr. Chris Elias leads the foundation’s efforts to strengthen the systems that make health care more accessible, equitable, and effective. The teams he oversees include Polio, Immunization, Emergency Response, Global Health Agencies and Funds, and Exemplars in Global Health. Across these areas, he focuses on partnership and system-level innovation—helping countries and global partners design lasting solutions that improve health outcomes for all. Before joining the Gates Foundation in 2012, Chris was president and CEO of PATH, an international nonprofit organization that works to advance global health through partnership, innovation, and evidence-driven approaches. Chris has an M.D. from Creighton University, where he later received an honorary doctorate, and an MPH from the University of Washington, where he was a fellow in the Robert Wood Johnson Clinical Scholars Program. He completed his residency in internal medicine at the University of California, San Francisco. He also received an honorary doctorate from the University of Pittsburgh. Chris is a member of the National Academy of Medicine.

June Yoshinari Davis leads the foundation's people-centered strategies across talent, culture, and organizational effectiveness, which includes human resources and diversity, equity, and inclusion. She joined the foundation in 2019 as director of strategy, planning, and management in the U.S. Program and chief of staff to the program's president. Before assuming her current role, she served as chief diversity, equity, and inclusion officer. With more than 20 years of experience spanning human resources, talent strategy, and organizational transformation, June has led high-impact people initiatives across the corporate, nonprofit, and philanthropic sectors. At Cargill, she served as a strategic HR business leader for several of the company's global businesses, leading talent planning, leadership development, workforce engagement, and cultural transformation. She also spearheaded key initiatives to integrate diversity and inclusion practices, policies, and systems into a US$100 billion organization with more than 150,000 employees across 70-plus countries. June's professional background also includes serving as senior managing director for people development at Teach For America and holding key roles in digital transformation, organizational strategy, and business development at Nike and Target, ensuring that talent, structure, and culture supported sustained business growth. She brings all of this deep expertise to her role as chief people officer and the foundation's vision for strengthening organizational effectiveness, equitable and inclusive partnerships, and lasting global impact. June has an A.B. in psychology from Harvard University and an MBA from Harvard Business School.

Ankur Vora oversees the foundation's work across Africa and India—two regions central to the foundation's global mission—and leads enterprise-wide strategy, advising the chair and CEO on priorities, resource allocation, and major tradeoffs across the portfolio. Ankur works closely with governments and partners to ensure strategies turn into measurable improvements in people's lives, particularly in places facing the greatest health and development challenges. He also helps guide the foundation's long-term strategic direction, including advising senior leadership on priorities and planning toward its intended closure in 2045. He is known for a practical, results-oriented approach that values collaboration, shared accountability, and honest problem-solving. Before joining the foundation in 2013, Ankur was director of programs at the Children's Investment Fund Foundation, where he managed investments across Africa and South Asia. Earlier in his career, he was a principal at the Boston Consulting Group and a lecturer in economics at the University of Chicago. He holds a Ph.D. in economics from the University of Chicago and serves on the boards of Global Health Labs and the Gates Medical Research Institute. Ankur's commitment to social impact is deeply influenced by his upbringing in India, where he saw his parents commit their lives to helping others.

Shana Tarbell is the foundation’s chief operating officer, responsible for driving much of the daily operations that enable the organization’s mission. She leads a broad portfolio of teams—including Facilities, Events, Travel, Security, Information Technology, People, and a small team focused on strategic cross-operational initiatives—and works closely with operational leaders to ensure that all functions are integrated, efficient, and aligned around a shared purpose. Previously, Shana served as the foundation’s Chief Security Officer for six years, overseeing all aspects of staff safety and security, including information security. She joined the foundation in 2015 as a deputy director on the Security team, bringing deep expertise in risk management and global affairs. Before entering philanthropy, Shana spent 18 years at the U.S. Central Intelligence Agency, where she served on the Senior Intelligence Service and held leadership roles addressing complex global challenges. In 2015, she received the federal government’s Meritorious Presidential Rank Award, recognizing her sustained excellence at the senior executive level—an honor awarded to no more than 5% of federal career senior executives. She also received the CIA’s Distinguished Career Intelligence Medal for exceptional service.

Alex Reid leads communications for the foundation and is responsible for the strategic use of voice to amplify the foundation’s philanthropic role and impact. She oversees all communications work including reputation and risk management, region-specific communications, creative and brand strategies, leadership voice and employee communications. Previously, Alex served as chief communications officer at Gates Ventures, where she set communications strategy for Bill Gates. She also spent nearly a decade working at the foundation from 2010-2019. During this time Alex expanded the foundation’s communications across Europe, oversaw program advocacy and communications strategy, and led high-profile campaigns, including Goalkeepers. Alex was born and raised in London and attended the University of Nottingham, where she earned a B.A. in politics. She lives in Seattle with her husband, two daughters, and a very playful golden doodle dog.

Lauren W. Bright leads the foundation’s legal team and is responsible for all legal matters and activities pertaining to the foundation and its affiliate organizations. In this capacity, she advises the foundation’s trustees, CEO, senior leadership, and staff on legal issues, is a member of the Executive Leadership Team, and serves as corporate secretary to the foundation’s board of trustees. Lauren’s responsibilities include managing global legal affairs, governance, conflict of interest issues, and legal risk management. Before her appointment as CLO, she served as the foundation’s co-general counsel and director of the foundation’s Washington, D.C., office. Before joining the foundation in 2005, Lauren worked at the law firm Pillsbury Winthrop Shaw Pittman, where she served nonprofit clients on a variety of legal issues, including governance, tax exemption, transactions, mergers, and legislative and regulatory issues. Over the course of her career, she has represented institutions and companies before the U.S. Congress and administrative agencies regarding federal education policies and programs. Lauren is the author of several articles on association practice and management and is a frequent speaker on legal topics affecting nonprofit organizations. She has also been a guest lecturer on legal issues affecting tax-exempt organizations at the University of Washington Law School Graduate Tax Program. Lauren received a J.D. from Villanova University’s Charles Widger School of Law and a bachelor’s degree from Gettysburg College, where she currently serves as Chair of the Board of trustees.

Carolyn Ainslie oversees the foundation's financial planning and management functions—including accounting, financial analysis, investment strategy and processes, risk and assurance, business management, and the Strategic Investment Fund—as well as strategy and planning more generally. In this role, she ensures that the foundation's resources are allocated wisely, to maximize the impact of our program investments and operations around the world. Before joining the foundation in 2018, Carolyn worked for 10 years as vice president for finance and treasurer at Princeton University, where she was responsible for the central financial functions of the university and, as a member of the president's senior staff, served as a key partner on strategic university initiatives. Earlier, she spent 10 years as vice president for planning and budget at Cornell University. Carolyn has an MBA in finance from the University of Rochester and a bachelor's degree from Bucknell University.

Mark Suzman leads the Gates Foundation in advancing its mission to ensure that every person has the opportunity to live a healthy, productive life. He is deeply committed to building partnerships and fostering a culture that contributes to meaningful impact. He is currently guiding an historic 20-year acceleration of the foundation's work ahead of its planned closure in 2045. During this period, the foundation will spend US$200 billion toward its goal of ensuring that no mother or child dies of a preventable cause, the next generation grows up in a world without deadly infectious diseases, and hundreds of millions of people can break free from poverty, putting more countries on the path to prosperity. Mark's upbringing in apartheid South Africa instilled in him a desire to use the advantages afforded to him to help tackle injustice and inequality. He began his career as a journalist, writing for Johannesburg's The Star and the Financial Times . In 2000, Mark went to work for the United Nations, where he helped implement the Millennium Development Goals under the leadership of Secretary-General Kofi Annan. He also served as senior advisor for policy and strategic communications in the Office of the Secretary-General and as policy director at the United Nations Development Programme. Mark joined the Gates Foundation in 2007 as the director of global development policy, advocacy, and special initiatives. He went on to serve as managing director of the foundation's country offices and then president of the Global Policy & Advocacy Division and chief strategy officer of the foundation. In the latter role, he oversaw expansion of the foundation's work in India, China, Africa, and Europe and managed partnerships with governments, private philanthropies, and civil society organizations. Mark has a doctorate in international relations from Oxford University, where he was a Rhodes Scholar, and a bachelor's degree from Harvard University.

Thomas Stahura remains an emeritus associate at Ascend after leaving its day-to-day analyst role, according to founder Kirby Winfield’s current announcement. He joined as an analyst in 2024 after graduating in engineering from Purdue. He co-founded AI startups Quasi and Pondr and built Ascend’s AI-enabled portfolio tracking, deal-flow management and internal automation, contributed technical diligence, helped portfolio engineers and created the Token Talks newsletter.

Nate Bek is Senior Associate and Head of Content at Ascend, promoted by founder Kirby Winfield following his earlier Associate role. He previously covered Pacific Northwest startups as a GeekWire reporter. He studied at the University of Hawaii at Manoa and led Honolulu ice-cream business Lucy’s Lab Creamery, developing an interest in entrepreneurship through operating experiments and partnerships.

Jen Haller is Partner and Chief of Staff at Ascend. She supports portfolio founders and firm operations, drawing on experience helping Seattle startups grow, including Ascend portfolio company Attunely through its Series A. She has extensive civic and volunteer involvement and participated in the first COVID-19 vaccine clinical trial.

Kirby Winfield founded Seattle venture-capital firm Ascend in 2019 and serves as its Founding General Partner. He invests in pre-seed AI startups and helps founders navigate customers, recruiting and later-stage financing. Before investing he held operating roles in four startups with four exits, including two IPOs and two acquihires. His current issuer biography also identifies him as a director and investor in Bean Box since 2016.

Shamini Chandran is listed by SPRIM Global Investments as Administrative Assistant. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Janice Wong is listed by SPRIM Global Investments as Accountant. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Amudhan Arumugam is listed by SPRIM Global Investments as IT Manager. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Maddy Hoang is listed by SPRIM Global Investments as Investment Analyst. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Juan Palazón is listed by SPRIM Global Investments as Financial Controller. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Published name: Michael Jackson. This profile refers to Fabric Ventures; existing namesake records are preserved.

Tina Leung publishes Treasure Play as her affiliation and describes experience in game art and UI design.

Melike Özcan describes her background in product management, growth and engagement and publishes Treasure Play as her affiliation.

Bertrand Lamarque built and led technology teams at Playfish and EA.

Andreas Risberg previously worked on the growth and product development of Candy Crush games.

Alex Arias previously founded gaming data platform Omniata, acquired by King in 2017, and held leadership roles at King, EA and Microsoft.

Shoin Wolfe leads analytics, growth and design at Mewtant/PixAI. His own profile identifies the role beginning in March 2026; the exact starting day is undisclosed.

Jiayu Liu is listed by Mewtant and describes his experience as engineering leadership and technical management.

Rissa Cao is a Mewtant co-founder and operating executive with experience in product development, consumer software and data-driven growth.

Raven Gao founded PixAI and leads its operator Mewtant; Stanford identified both roles at its June 2, 2026 AI and media startups event.

Leads Foresite Labs therapeutics strategy and company creation; published as Foresite Capital Venture Partner.

Evaluates public and private biotechnology investments.

Leads clinical development strategy for Foresite Labs incubations and supports Foresite Capital scientific diligence as Venture Partner.

Founded Foresite Capital in 2011 and leads healthcare company investment and creation at the intersection of biology, AI and engineering.

Leads investor relations, capital formation and strategic business initiatives.

Leads compliance and supports investment-firm legal matters.

Leads therapeutics investing across incubation, private financings and public markets.

Leads Foresite Labs scientific strategy, company creation and portfolio development in AI and biomedicine; published as Foresite Capital Venture Partner.

Leads human resources; current Director title supersedes older Senior Associate wording in the biography.

Advises the life-sciences investment team.

Sources and evaluates healthcare technology and services investments.

Provides executive assistance to the investment team.

Supports administration and internal processes.

Oversees research and development evaluation for healthcare investments.

Healthcare adviser supporting medicine discovery, development and commercialization.

Leads investor relations and business-development work.

Foresite Labs venture partner launching and building incubated companies while supporting Foresite Capital.

Evaluates investments through diligence and financial modeling.

Healthcare venture partner with earlier leadership in GRAIL’s operations and commercialization.

Supports executive administration and operations.

Reconciles public and private holdings and records trading activity.

Venture and growth-company legal adviser; founding partner and chairman emeritus of Gunderson Dettmer, an external legal firm.

Supports limited partners, investor communications and capital formation; current Director title takes precedence over older Associate Director biography wording.

Supports the CEO’s office.

Reviews fund financial activity, reconciliations and quarterly reporting.

Evaluates therapeutics investment opportunities.

Provides executive administration for investment professionals.

Evaluates biotechnology investment opportunities.

Supports fund transactions and legal matters.

Physician and investor evaluating private and public biotechnology companies.

Foresite Labs operating partner building companies at the intersection of AI and biotechnology; published as Foresite Capital Venture Partner.

Provides executive support to the CEO’s office.

Advises on sourcing, diligence, portfolio oversight and healthcare company incubation.

Develops and maintains investment-firm compliance processes.

Coordinates accounting, capital calls, distributions and cash management.

Invests in life sciences and healthcare technology; previously developed healthcare partnerships at Verily.

AI and life-sciences adviser; co-founder and CEO of the distinct Foresite Labs company-building platform.

Monitors private investments and leads portfolio valuation; current Director title supersedes older Manager wording in the biography.

Healthcare adviser and former US Secretary of Health and Human Services, serving in government from 2018 to 2021.

Physician-scientist evaluating biotechnology and healthcare investment opportunities.

Provides executive support to investment and investor-relations leadership.

Supports portfolio companies with positioning and communications.

Supports companies commercializing research and innovation.

Evaluates technologies in chemistry, energy and novel memory devices.

Electrical and biomedical engineering professional supporting deep-tech founders.

Former photonics startup CEO supporting technology-driven companies.

Bioengineer with medical-sciences doctoral training supporting product development and commercialization.

Electrical engineer and integrated-circuit designer investing in semiconductor and photonics technologies.

Technology R&D and venture investor supporting startup strategy and international growth.

Health-technology investor supporting early-stage companies through growth and exits.

Repeat entrepreneur supporting technical feasibility, differentiation and scaling.

SHOPLINE president and technology executive. Provides ecommerce infrastructure and serves on F&F Ventures’ investment committee.

Consumer packaged goods entrepreneur with two ecommerce exits and co-founder of Protein Waffles.

Built a distribution business to USD18 million in two years and has experience in consumer goods, supply chains and private equity.

Founded Founders & Funders, built and sold a consumer business to private equity, and has made more than 40 angel investments.

Chang Chu Chuen is listed by SPRIM Global Investments as Senior Investment Analyst. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Chong Wee Khoo is listed by SPRIM Global Investments as Director of Accounting & Compliance. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Hartini Ismail is listed by SPRIM Global Investments as Group HR Manager. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Daniel Martinez is listed by SPRIM Global Investments as VP Clinical Trials Financing. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Adele Hosseini is listed by SPRIM Global Investments as Venture Director. The published venture affiliation does not establish full-time employment.

Joti Marango is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Igor Matushansky is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Nick Srikanth is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Guillaume Pfefer is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Elizabeth Wang is listed by SPRIM Global Investments as TrialCap, Director, Credit Structuring. This capacity belongs to SGI’s clinical-trial financing platform.

Sylvain Labattu is listed by SPRIM Global Investments as Managing Director, TrialCap. This capacity belongs to SGI’s clinical-trial financing platform.

Gonzalo Rubio is listed by SPRIM Global Investments as TrialCap, Partner. This capacity belongs to SGI’s clinical-trial financing platform.

Al Hummel is an SGI senior partner. His own biography describes healthcare operating and capital-markets experience, including leadership at Obagi Medical Products, Cobrek Pharmaceuticals and Watson Pharmaceuticals. These outside positions are historical career context.

Thomas Fratacci is published as partner and group CFO in SGI’s current team. His own biography describes group finance, financing-round and exit work, with earlier financial audit and WPP/Kantar executive experience.

Ivan Jarry is SGI’s co-founder and managing partner. His own biography describes developing SPRIM’s international healthcare operations and overseeing SGI’s R&D-services portfolio since2015, with business-management training at EDHEC.

Michael Shleifer is SGI’s co-founder and managing partner. His own biography describes doctoral training in pharmacology, earlier work at L’Oréal, co-founding the SPRIM operating business and developing SGI’s biotech and clinical-trial financing strategies. The consulting business and investment firm chronologies are distinguished.

Alison MacDonald is named by the University of Oxford as Interim Head, Department for Continuing Education in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Lindsay Rudge is named by the University of Oxford as Divisional Registrar and Chief Operating Officer, Gardens, Libraries and Museums in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Simon Hiscock is named by the University of Oxford as Director of Botanic Garden in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Silke Ackermann is named by the University of Oxford as Director of History of Science Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Gavin Svenson is named by the University of Oxford as Director of Oxford University Museum of Natural History in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Alexander Sturgis is named by the University of Oxford as Director of Ashmolean Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Laura van Broekhoven is named by the University of Oxford as Director of Pitt Rivers Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Richard Ovenden is named by the University of Oxford as Head of Gardens, Libraries and Museums; Bodley’s Librarian in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Simon Boddie is named by the University of Oxford as Chief Financial Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Simon Boddie is an Oxford University Innovation non-executive director and University of Oxford Chief Financial Officer. His current OUI biography dates his Oxford Science Enterprises representative board service from2021 to early2026 and Learning Technologies Group directorship to2025. Earlier work included 15 years on boards of FTSE250 businesses.

Saira Shaikh is named by the University of Oxford as Academic Registrar in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Andrew Mackie is named by the University of Oxford as Director of Legal Services and General Counsel in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Tim Soutphommasane is named by the University of Oxford as Chief Diversity Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

David White is named by the University of Oxford as Chief Digital and Information Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Liesl Elder is named by the University of Oxford as Chief Development and Alumni Engagement Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Gillian Hamnett is named by the University of Oxford as Deputy Academic Registrar, Strategic Business Change; Interim Proctors’ Office in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Jackie Hoyle is named by the University of Oxford as Deputy Academic Registrar, Education Services in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Timothy Power is named by the University of Oxford as Head of Social Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own current Social Sciences biography describes a comparative political scientist researching democratization and political institutions in Latin America, especially Brazil; he leads the division and participates in University Council.

James Naismith is named by the University of Oxford as Head of Mathematical, Physical and Life Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own MPLS profile identifies James (Jim) Naismith as the current division head, with published research in molecular structure, enzymes and biological chemistry. This living Oxford academic is distinct from the historical basketball inventor.

Dan Grimley is named by the University of Oxford as Head of Humanities Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own Humanities leadership profile confirms that Daniel (Dan) Grimley heads the division and oversees its academic strategy, planning and financial management; he is a musicologist.

Bríd Cronin is named by the University of Oxford as Divisional Registrar, Social Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Chris Price is named by the University of Oxford as Divisional Registrar, Medical Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Tracy Gale is named by the University of Oxford as Divisional Registrar, Mathematical, Physical and Life Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Alex Vincent is named by the University of Oxford as Divisional Registrar, Humanities in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Lorna Thomson is named by the University of Oxford as Director of Research Services in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Antony Willott is named by the University of Oxford as Director of Planning and Council Secretariat in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Markos Koumaditis is named by the University of Oxford as Director of Human Resources in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Iain Critchlow is named by the University of Oxford as Interim Director of Estates in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

James Colman is named by the University of Oxford as Director of Communications in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Lukasz Bohdan is named by the University of Oxford as Director of Assurance in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Oxford’s October 2026 officer roster explicitly names Lionel Tarassenko as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Reuben College; biomedical-engineering and machine-learning researcher. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Aziz Sheikh as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Head of the Nuffield Department of Primary Care Health Sciences. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Nigel Shadbolt as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Principal of Jesus College; artificial-intelligence and computer-science researcher. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Jennifer Payne as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Warden of Merton College. This university governance role does not establish personal cash investments or employment at a venture fund.

Muneeb Ahsan is named as a software developer and data analyst in the older English company directory. This is a dated published relationship to Portabiles HealthCare Technologies; the newer German roster does not establish a current operational appointment. The directory provides a logo placeholder rather than a genuine portrait, so no substitute headshot is uploaded.

Oxford’s October 2026 officer roster explicitly names Helen Moore as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Corpus Christi College. This university governance role does not establish personal cash investments or employment at a venture fund. The academic is distinct from the existing same-name venture-investment professional.

Nicole Pohlschmidt is named as Head of Digital Medical Support in the older English company directory. The2024 financing post also references her account but does not define a separate current appointment. The company directory uses a logo placeholder for her image; this is retained as a genuine portrait gap, while current employment dates and wider credentials remain unclaimed.

Oxford’s October 2026 officer roster explicitly names Jonathan Michie as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Kellogg College. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Michael Jacobs as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Warden of Keble College. This university governance role does not establish personal cash investments or employment at a venture fund.

Malte Ollenschläger is listed as a software developer and data analyst in the older English Portabiles HealthCare Technologies directory. His documented function concerns software and analysis supporting the company’s wearable-health technology. Present employment, broader biography and exact appointment dates require further primary material.

Oxford’s October 2026 officer roster explicitly names Sarah Foot as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Dean of Christ Church. This university governance role does not establish personal cash investments or employment at a venture fund.

Anselm Hochschild is named as a software developer and data analyst in the older English company directory. This establishes a published operational relationship to the digital-health business; it does not establish his present employment or any personal financing contribution. The older publication is retained with a current-status qualification.

Oxford’s October 2026 officer roster explicitly names Judith Buchanan as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Master of St Peter’s College. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Sue Black as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of St John’s College. This university governance role does not establish personal cash investments or employment at a venture fund.

Karthik Ayyalasomayajula is listed as a software developer and data analyst in Portabiles HealthCare Technologies’ older English directory. The published function supports digital products and data analysis in a wearable gait-analysis business. Current appointment status and dates remain undisclosed rather than inferred from an older live web page.

Published as Interim Registrar in the July 2026 direct-report chart and current October university officer roster. The interim appointment is distinguished from previous Deputy Registrar and predecessor Registrar posts.

Susanne Sand is named as a project assistant in the older English company directory. Her relationship is qualified to that published roster, since the newer German page does not confirm a current operational appointment. The company substitutes a brand logo for her directory image; no portrait is fabricated or represented as available.

Professor of Cognitive Neuroscience studying brain plasticity and recovery after injury; former 2015–2025 Wellcome Centre for Integrative Neuroimaging director. Leads cross-university initiatives including the proposed Warneford Park brain and mental-health campus.

Hayat Koubaa is named as Head of Business and Product Marketing in the older English Portabiles HealthCare Technologies directory. This documents a business and product-marketing role in the digital-health company; the page’s2023 metadata and newer roster differences are retained. Current employment, qualifications and appointment dates require further primary evidence.

Oxford Vesuvius Professor of Materials researching batteries, additive manufacturing and power-generation alloys; previously headed the Materials Department and is a non-executive director of Oxford University Innovation. Distinct from the same-name Outlier Ventures analyst. The academic is distinct from the existing same-name venture-investment professional.

Physics and materials researcher specializing in solid-state nuclear magnetic resonance; formerly led Lancaster and Southampton universities. Began the Oxford portfolio in June 2026, without an inferred exact day.

Stefan Schulz is named as head of development in the older Portabiles HealthCare Technologies English directory. The published function relates to development of the company’s digital and sensor-based products. Current appointment status, career history and exact dates are not provided by the newer directory and are not invented.

Professor of Politics and former DPIR head, researching comparative political economy and migrant remittances. The latest July 2026 organizational chart gives appointment start September 2, 2026; current October officer page confirms appointment.

Chantal Herberz is identified as Head of Product Strategy in the older English company directory and appears as the author of primary issuer financing and innovation-program announcements. The company develops wearable and digital services for movement-disorder care. Her directory role is qualified to the older publication; a later outside affiliation is not overwritten or treated as simultaneous company employment without evidence.

Oxford statutory professor of Biomedical Engineering, researching therapeutic ultrasound and drug delivery; co-founded OrganOx, OxSonics and OrthoSon. Began the innovation portfolio in April 2026; exact day undisclosed. Constantin Coussios serves as an Oxford University Innovation non-executive director and University of Oxford Pro-Vice-Chancellor for Innovation. He holds Oxford’s statutory biomedical-engineering chair and Cambridge MEng/PhD degrees. His academic entrepreneurship includes OrganOx, OxSonics and OrthoSon, developing technologies including therapeutic ultrasound and medical devices.

Julius Hannink is named as an algorithm specialist in Portabiles HealthCare Technologies’ older English directory. His documented company function concerns analytical methods supporting sensor-based movement analysis. The directory remains publicly accessible but was last dated2023 and differs from the newer German roster, so present employment and precise start/end dates are unconfirmed.

Professor of Forced Migration and International Affairs and co-founder of the Refugee-Led Research Hub. Began this university portfolio in June 2025; exact day undisclosed.

Jörg Stein is identified as CFO in the older English company directory and2024 financing announcement. His own M&P consulting announcement describes support for founder Ralph Steidl’s team as CFO from spring2020, and a current Radiomics biography calls the role interim CFO. He has medical-device financing, strategy and business-development experience; his latest exact appointment status requires confirmation against the newer German company directory, which omits this role.

Professor of English whose research concerns eighteenth- and nineteenth-century literature. Oversees teaching, learning, admissions and student support.

Professor of Anaesthetic Neuroscience, researching pain perception and anaesthetic consciousness with advanced neuroimaging; former Merton Warden and founding FMRIB scientist. Irene Tracey is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2026 and research/prize committee member. Oxford Vice-Chancellor and anaesthetic-neuroscience professor with neuroimaging/pain research and scientific-leadership experience; previously Brain Prize selection-committee member.

Sabine Stallforth is a neurology specialist identified in the University Hospital Erlangen care-partner section of the Portabiles HealthCare Technologies directory. Her published relationship supports ParkinsonGo’s clinical service. She is recorded as an external clinical partner rather than presumed company staff; additional current hospital titles are not inferred.

Former UK foreign secretary and Oxford PPE alumnus; elected November 2024 and admitted to university office on February 19, 2025.

Teresa Greinwalder provides nurse-service support through University Hospital Erlangen, identified by the company as a care partner for ParkinsonGo. The own directory places her under the external hospital-partner section, rather than company management. This relationship concerns service delivery and is not represented as direct company employment or a financing participation.

Björn Eskofier is a co-founder and scientific advisor of Portabiles HealthCare Technologies. The company combines machine learning, wearable movement data and neurological-care research. His own2024 public financing post corroborates a staged equity fundraising and his company affiliation, while current own company material identifies his scientific advisory role. Personal cash participation is not inferred from announcing institutional funding.

Jürgen Winkler is a medical advisor named by Portabiles HealthCare Technologies in its current German directory. His advisory relationship is associated with neurological care and the company’s gait-analysis services for movement disorders. The published directory does not call him a company co-founder, so that title is not inferred. Additional appointments and personal investment amounts require separate primary proof.

Jochen Klucken is a medical co-founder and advisor of Portabiles HealthCare Technologies. The own current directory identifies his medical advisory capacity; the company’s origin links neurological research with wearable gait measurement and data analytics. His contribution is qualified as advisory involvement, without inferring ownership percentages, clinical efficacy or additional current university appointments.

Ralph Steidl founded Portabiles HealthCare Technologies and leads the company as CEO. Its current legal notice names him as the authorized representative. His work connects the company’s wearable gait-analysis technology with ParkinsonGo’s clinical and nurse-supported service. The company grew from university and hospital research into a digital-health business; institutional financing is not treated as a personal investment.

Physician and pharmaceutical professional with experience as an emergency physician and medical manager in oncology. Holds an ESADE MBA and sources and analyzes investments for We Venture Capital.

Life sciences investor with experience supporting early-stage funds at BioCity and working with portfolio boards. Previously held commercial roles at venture-backed startups and studied analytical chemistry.

David Chang is the ophthalmologist and past president of the American Society of Cataract and Refractive Surgery named by Iantrek as an adviser. He is distinct from the biotechnology executive DavidChang already in the database.

Iqbal “Ike” Ahmed is a glaucoma surgeon named on Iantrek’s testimonial panel. The panel labels him Chief Medical Officer, but the company’s explicit2025leadership announcement and current board identify Sean Ianchulev as CMO. Ahmed is recorded as a qualified clinical-advisory affiliation, without asserting a simultaneous current executiveappointment.

Stephen Bloch is a current Iantrek board observer and Canaan Partners general partner. OlderSECfilings list director; current company observer designation is recorded without guessing transitiondate.

Andrew Corley is a current Iantrek board observer and is identified by the company as co-founder of Flying-L Partners. OlderSECfilings list director; current own directory observer takes precedence without inventing transitiondate.

Advises on global pharmaceutical strategy and commercialization, with experience translating clinical technologies to commercial use at Roche, Novartis and MSD.

Advises on ecosystem strategy, drawing on pharmaceutical strategy and consulting experience across pharma, medical technology, payers and providers.

Advises on commercial strategy and global market access, with 15 years supporting international expansion, adoption and reimbursement of healthcare technologies.

Advises on regulatory affairs and clinical laboratories, drawing on almost three decades at Mayo Clinic and experience in laboratory-developed tests, laboratory standards and FDA pathways.

Advises on translational immuno-oncology and ex vivo platforms, with academic research experience at MIT, Harvard Medical School, Dana-Farber Cancer Institute and Massachusetts General Hospital.

PhD in Biochemistry with nearly 30 years of pharmaceutical and biotechnology company development experience; former longtime CEO of DelSiTech and co-founder of Laurantis Pharma and BioCis Pharma.

BSc in Cell and Molecular Biology.

PhD in Biochemistry.

MSc in Molecular Biosciences and BEng in Biotechnology.

MSc in Cell Technology, class of 2026.

MSc in Translational Medicine and PhD candidate.

Organ-on-chip and microphysiological systems researcher, head of the 3R-Center Tübingen and professor at the Natural and Medical Sciences Institute and University of Tübingen.

Cancer researcher with more than 20 years of experience, including Harvard Medical School and Dana-Farber Cancer Institute; specializes in translational cancer biology, functional precision medicine and patient-derived cancer models.

Healthcare executive with 30 years of experience in business development, commercialization and company growth and transformation; MSc in health, BSc in pharmacy and EMBA.

MD and PhD, ENT specialist and otologist with more than 17 years of clinical and academic experience.

Aalto University MSc with 15 years of product development experience in medical, security and climate technology, including Philips Medical Systems MR Finland and KaVo Kerr.

Clinical engineer in audiology with a PhD and more than 15 years of clinical and academic experience in acoustics, audiology and electrical engineering.

MBA with experience in project coordination, operations, customer relationships, sales and marketing across international markets.

Healthcare executive with more than 20 years of experience in growth, multisite operations and mergers and acquisitions across medical devices, specialty care and consumer health.

Jeffry Weinhuff is a current Iantrek board member and Visionary Ventures partner. IantrekSECfilings use JeffryK.Weinhuff and JeffreyK.Weinhuff name variants; the company directory and matching ophthalmic investment affiliation establish one person.

Adam Szaronos is Iantrek’s chief executive officer and a board member, appointed inFebruary2025 to lead commercialisation of its glaucoma surgical products. He succeeded founder Sean Ianchulev, who retained chairman/CMO responsibilities.

Sean Ianchulev founded Iantrek and remains its chairman and chief medical officer following Adam Szaronos’s2025CEOappointment. He is a professor of ophthalmology at New York Eye and Ear of Mount Sinai and an ophthalmic surgical-device innovator. CompanySECfilings use Tsontcho Ianchulev for the corresponding founder/executive; no separate person is inferred from the formal-name variant.

Pharmaceutical strategy and clinical-development executive appointed to Cilcare’s board on December 2, 2024. The January 2025 announcement describes her Catalyst Pharmaceuticals chief strategy role and earlier Sanofi, Abbott, Covance and Neurovision experience; later tenure has not been independently confirmed.

AI and machine-learning professional and managing director of AltGR. Cilcare names him an external acting Chief Data Officer overseeing data strategy, databases and auditory-signature projects.

Pharmacology expert in otologic and neurologic diseases, previously Chief Scientific Officer at Otonomy. Has worked on local inner-ear drug-delivery technologies and hearing-therapy development.

Physician, HEC graduate and healthcare strategy consultant with pharmaceutical and biotech experience. Advises on market access, real-world evidence, health authorities and the transition from R&D to commercial operations.

ENT surgeon and neuroscience researcher at CHU Montpellier, specializing in hearing-loss treatment and cochlear implants. Participates in Cilcare clinical research and studies auditory therapeutic strategies.

Endocrinologist and diabetologist who co-founded France’s Institute of Diabetology and Nutrition of the Centre. Contributed to Cilcare’s DIAMANT observational study of auditory profiles in diabetic patients.

ENT surgeon and auditory researcher at CHU Bicêtre in Paris. Studies auditory-nerve regeneration and cochlear synaptopathy, including preclinical synapse-repair approaches and CIL001 development.

Audiologist and auditory-neuroscience researcher whose work addresses hearing loss, tinnitus and associated cognitive conditions. His Cilcare biography describes teaching at Worcester State University and patient-care work in hearing organizations.

Clinical audiologist and researcher at Ear Science Institute Australia studying the relationship between hearing loss and cognitive impairment. Her published work includes the HearCog hearing-intervention trial.

Pharmacologist with pharmaceutical drug-discovery experience, including departmental leadership at Sanofi. Cilcare’s biography names him head of drug discovery and preclinical research at Fraunhofer ITMP.

Auditory scientist and clinical audiologist researching cochlear synaptopathy and measures of hidden hearing loss. Combines animal-model research with human electrocochleography and clinical auditory assessments.

Auditory researcher at the State University of New York at Buffalo, with work spanning tinnitus, neural plasticity, ototoxicity and age-related hearing loss. Advises Cilcare on preclinical hearing models and their translation to clinical research.

Auditory researcher specializing in cochlear disorders, tinnitus and hearing-loss measurement. Cilcare names him honorary president of its scientific advisory board and describes his longstanding translational-science mentorship.

Finance manager responsible for Cilcare budgeting, financial analysis, cash-flow planning and administrative coordination. Her company biography describes more than twenty-five years of financial-management experience.

Quality-systems manager responsible for Cilcare quality processes, audits and continuous improvement. Previously worked as a quality engineer in dermocosmetics, coordinating subcontractor specifications and audit procedures.

Administration and HR manager supporting Cilcare employee relations, administrative processes and workplace coordination. His background includes education, tourism and multilingual cross-cultural communication.

Infrastructure and real-estate operations leader involved in Cilcare laboratory development since its founding. Previously directed quality at Cilcare and worked in pharmacology at Sanofi; oversees worksites, IT infrastructure and compliance.

Data scientist specializing in pharmacometrics, machine learning and predictive tools for auditory datasets. Previously worked in Sanofi’s clinical pharmacometrics and programming team on pharmacokinetic simulations and neural-network methods.

Full-stack developer building Cilcare clinical-research dashboards and secure internal applications. Previously developed JavaScript applications at Smile, including work for Suez.

Data-science and AI engineer leading Cilcare’s data architecture and analysis of preclinical and clinical auditory measurements. Works on digital auditory signatures and biomarker methods for precision medicine.

Pharmacist and innovation-management professional coordinating drug-development projects and clinical-trial regulatory submissions. Previously worked on medical-care licensing at Pierre Fabre and innovation commercialization at CHU Montpellier.

Clinical audiologist and trials manager with US clinical-practice and ENT experience. Previously monitored a Frequency Therapeutics study; now supports audiology protocols, training and auditory-signature research at Cilcare.

Drug-development project manager with pharmaceutical, clinical-trial and preclinical program experience. Previously led pharmacology work at Galderma; now coordinates CIL001 clinical development and related regulatory and CMC activities.

Clinical-trial manager supporting Cilcare’s DIAMANT and SAPHIR observational studies. Previously worked for seventeen years as a surgical-unit nurse and now contributes to auditory assessments and clinical data collection.

Clinical-trial manager specializing in auditory electrophysiological and electroacoustic assessment. Coordinates Cilcare therapeutic studies, clinical protocols, recruitment and investigational-product supply.

Senior scientist working on preclinical auditory studies and hearing-therapy development. Previously conducted hearing-loss research at Creighton University’s Richard Bellucci Translational Hearing Center.

Neuroscientist and audiologist specializing in hearing disorders, histology and translational research. Previously researched sensorineural hearing loss at Montpellier’s neuroscience institute and Harvard Medical School.

Executive assistant to Cilcare’s COO with experience in digital strategy, IT project management and business development. Coordinates leadership schedules, communications and cross-team strategic projects.

Market-development professional connecting Cilcare research services with global clients and strategic partners. Previously led a Canadian life-sciences startup and worked in business development at CNRS.

Preclinical research scientist with molecular and cellular biology experience spanning neuroscience and gene therapy. Supports animal experiments, behavioral testing, imaging and histology for hearing research.

Preclinical study manager with expertise in in-vivo pharmacology, gene therapy, immunohistochemistry and auditory-tissue gene transfer. Supports research studies, laboratory operations and client reporting.

Preclinical hearing researcher specializing in inner-ear microsurgery and rodent and large-species studies. Previously worked at Decibel Therapeutics on efficacy, toxicity and biodistribution experiments.

Software and medical-instrumentation engineer supporting Cilcare’s Montpellier and Boston laboratories. Develops data-acquisition, signal-processing and AI tools; previously worked on audiological systems at Echodia.

Neurobiology researcher and preclinical study manager experienced in murine pharmacology, stereotaxic surgery and histology. Her University of Montreal research included spinal-cord cell models and differentiation analysis.

Inner-ear histology scientist working at Cilcare’s Lexington, Massachusetts laboratory. Previously worked in auditory histology at Decibel Therapeutics and contributes to electrophysiology and study design.

Preclinical study manager with experience in regenerative medicine, cell therapy and inflammation research at CHU Montpellier. Previously managed research projects and purchasing at a biotech company.

Assistant project manager with training in life sciences, molecular biology, microbiology and immunology. Supports Cilcare experimental studies and holds an animal-experimentation certificate.

Preclinical scientist with experience in electrophysiology, cochlear histology and in-vitro and in-vivo experiments. Previously studied drug mechanisms for neurodegenerative and psychiatric diseases.

Preclinical-operations director with cell-therapy and murine-model research experience. Previously led an in-vivo model platform in Montpellier; now oversees study design, execution and reporting for Cilcare clients.

Medical-writing and program-management professional with biopharmaceutical experience. Supports research quality control, regulatory compliance and coordination among study teams and service providers.

Pharmacology laboratory professional managing Cilcare equipment, technical operations, safety and maintenance. Supports preclinical model development, experimental methods and research data management.

Leads Cilcare’s US preclinical operations with expertise in electrophysiology, microsurgery, histology and in-vivo study design. Previously contributed to cancer-therapy and biosensor R&D programs.

Neuroscientist whose 2024 doctoral research developed an awake-animal model for tinnitus and hyperacusis with Cilcare and Institut Pasteur. Specializes in electrophysiology and tinnitus assessment using GPIAS.

Auditory-neuropathy scientist leading histology and ex-vivo programs. Works on synapse analysis, electrophysiological assessment and biological sampling for preclinical hearing research.

Preclinical program leader specializing in cochlear histology, electrophysiology and inner-ear surgery. Her earlier research investigated cellular mechanisms of drug-related and age-related hearing loss.

Preclinical research manager specializing in neurotology study planning, resources and logistics. Her responsibilities include Montpellier laboratory studies, pharmacokinetics, inner-ear surgery and local-tolerance assays.

Research and commercial leader with academic and industrial experience in otology and CNS research. Manages Cilcare strategic alliances and CRO partnerships, supported by in-vitro and in-vivo research expertise.

Anesthesiologist and intensive-care physician with experience in neurosurgery, interventional neuroradiology and trauma care. Leads Cilcare translational research, observational hearing studies and auditory-biomarker validation.

Pharmacist leading Cilcare’s evidence, value and access strategy across health economics, market access and clinical outcomes. Previously worked at Sanofi in global and affiliate health-economics roles in Boston and Paris.

Cilcare marketing and communications leader responsible for brand strategy, communications material and digital initiatives. Her company biography describes more than fifteen years of professional experience.

Biopharmaceutical medical executive overseeing Cilcare’s medical strategy and hearing-therapy clinical development. Previously served as Chief Medical Officer at Auris Medical and has experience with public-company financing and investor relations.

Neuroscience drug-development professional with previous experience at Pfizer and Servier. Leads Cilcare’s early pipeline development, in-licensing, research collaborations and co-development assessment.

Clinical-operations leader with experience taking therapeutic-protein programs from preclinical research into clinical development. At Cilcare he designs development strategies for drug candidates addressing ear disorders.

Cilcare team member since 2015 with neuroscience and preclinical-development experience, including electrophysiology and intracochlear delivery. The current directory names her General Manager for Japan and Asia; its biography also describes earlier US laboratory and operational-excellence responsibilities.

Life-sciences finance and digital-transformation executive responsible for Cilcare’s financing and data strategy. Previous Sanofi positions included CFO in Poland and R&D finance leadership in Asia-Pacific.

Scientific and operations leader with research experience developing animal models of depression, Alzheimer’s disease and neuroinflammation in France and Canada. Her work connects CNS disease research with auditory drug development.

Cilcare co-founder and compliance leader with a pharmaceutical drug-development and regulatory background. Previously directed an international regulatory department at Sanofi and worked on aging-related hearing disorders.

Cilcare co-founder and preclinical-innovation director whose research covers tinnitus, hearing loss and in-vivo pharmacology. Previously led scientific teams at Sanofi across hearing, aging, cardiology and oncology.

Cilcare co-founder and CEO with a background in pharmaceutical R&D and hearing disorders. Previously led clinical-trial logistics and supply chains at Sanofi and worked on aging-related chronic-disease programs.

Matt Walker led Shire technicaloperations after joining in2016, following engineering and supplyoperations atPfizer. He is distinct from the S2Ginvestor and UCLneurologist MatthewWalker records.

Kim Stratton led Shire’s internationalcommercial business in the pre-acquisition directory. Her previous work included internationalpharmaceutical leadership and nursing.

Perry Sternberg led Shire’s UScommercial business in the pre-acquisition directory, following pharmaceutical and ophthalmiccommercial experience. This is a historical leadership attribution.

Andreas Busch is the pharmacology executive who became Shire’s R&Dhead and chiefscientificofficer inJanuary2018, following drugdiscovery leadership at Bayer. He is distinct from the youngerDanishCernelecommercefounder of the same name.

Responsible for financial reporting, metrics and governance, with a focus on efficiency and digital transformation.

Develops computer vision technology to improve ANCELIA’s monitoring capabilities.

Leads ANCELIA’s expansion into Spain and Portugal.

Co-founder with a biomedical engineering doctorate who leads product development and customer needs at TeiaCare.

Co-founded TeiaCare after family experience with residential care prompted him to develop technology supporting caregivers and residents.

Principal at We Venture Capital with transactional and business advisory experience. His own investor biography explicitly qualifies the Zetta board seat as prior to exit; no exact appointment or end date is supplied.

Head of We Venture Capital, a physician and life science investor. The investor’s published team biography identifies her Zetta observer affiliation; post-exit continuation is unverified.

Genomics product specialist whose earlier product roles include Congenica and Prenetics. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Clinical scientist and genomics quality specialist; former Head of Bioinformatics Quality at Genomics England, with experience implementing quality systems and IVD and ISO compliance. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Chartered people professional focused on building technology and healthcare teams, employee experience and development. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Life sciences commercial leader with experience in clinical trial sequencing, product strategy and European software sales. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Software entrepreneur and board adviser with experience founding and scaling businesses and designing leadership strategy programs. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Founder and architect of XetaBase and OpenCB. Published company biography identifies him as Ignacio Medina; TriNetX’s April 7, 2026 acquisition announcement supplies his full name and confirms CEO/CTO roles. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Healthcare commercial executive and former IQVIA global lead for drug discovery and development consulting. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Life sciences executive whose published biography describes experience in international expansion, partnerships and product launches at SOPHiA Genetics and Foundation Medicine. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Financial and operations leader with more than twenty years of experience across large public companies and technology startups. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Bill Mordan was Shire’s pre-acquisition general counsel and companysecretary. He previously held legal roles at ReckittBenckiser and Procter&Gamble; no currentindependentShire role is implied.

Joanne Cordeiro was Shire’s pre-acquisition chief humanresources officer after joining the company in2011. The historicaldirectory records her2017 appointment and earlier technologyindustryHR experience.

Jeffrey Poulton was Shire’s CFO and executive director throughDecember31,2017. This explicitlyformer role follows his earlier companyfinance and businessunit leadership; it is not a current appointment.

Albert Stroucken, also called Al, served as a historical Shire nonexecutive director with internationalmanufacturing experience, including Owens-Illinois and H.B.Fuller.

Anne Minto served as a historical Shire nonexecutive director with legal and humanresources experience. The2017 report announced planned retirement following its2018 AGM.

Sara Mathew served as a historical Shire nonexecutive director, with finance and technologyleadership experience including Dun & Bradstreet. The role is explicitly pre-acquisition.

David Ginsburg is a physician and biomedical researcher who served as a historical Shire nonexecutive director. His published background includes hematology and genetics research at Michigan and HHMI.

Olivier Bohuon served on Shire’s pre-acquisition board following pharmaceutical and healthcare leadership. Its report announced a future seniorindependentdirector appointment after the2018 AGM; the planned change is qualified.

Gail Fosler served as a historical Shire nonexecutive director, bringing economics and corporateadvisory experience. Her published historical role is distinct from any currentShireemployee attribution.

Ian Clark served as a historical Shire nonexecutive director following leadership at Genentech and Roche. His role here is limited to the published pre-acquisition directory.

Dominic Blakemore served as a historical Shire nonexecutive director with finance and corporateleadership experience. Its report announced planned retirement following the2018 AGM; no currentShireboardclaim is made.

Thomas Dittrich was Shire’s incoming2018 CFO and executive director, following finance leadership at Sulzer and Amgen. The report’s scheduledMarch19,2018 appointment is distinguished from evidence of an actual completed appointment.

Flemming Ornskov was Shire’s pre-acquisition chief executive and a physician by training. His CEO-designate appointment inJanuary2013 preceded his actual CEO appointment inApril2013; no current independentShireCEO role is asserted.

Susan Kilsby chaired Shire before its acquisition, following senior investment-banking roles. Shire’s2017 report distinguishes her2011 board entry from her2014 chair appointment.

Mecoly Dong is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

AnneMarie Bott is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Amy Zhen is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Alana Green is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Anna Bitton is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Frank Gao is published in Dimension’s current research team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Bauer LeSavage is on Dimension’s current Research team. Stanford Bio-X independently identifies him as a Dimension research associate investing in platform biotechnology at the intersection of life science and technology. His Stanford2018 bioengineering fellowship researched scalable hydrogels for expanding human neural stem cells, advised by Sarah Heilshorn and neurosurgeon Theo Palmer. Dimension’s ownJune2026 post specifically credits his work on training data for biological AI models; research proposals are not clinical efficacy claims.

Simon Barnett is on Dimension’s current Research team. His prior primary2022 GEN speaker biography confirms genomics-analysis work at ARK, including DNA sequencing, molecular diagnostics, bioinformatics and synthetic biology. His primary ARK research2023 identifies his earlier life-sciences research leadership. Those historical employer titles are not asserted as current alongside Dimension.

Nikhil Namburi is published in Dimension’s current investment team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Adam Goulburn is a Dimension co-founder and managing partner, identified in the firm’s March2026 SEC adviser filing as Adam Lander Goulburn. His primary BIO historical speaker biography documents life-sciences investing, neuroscience, brain-computer interfaces and stem-cell research, earlier Lux Capital work, a neuroscience postdoctoral fellowship at Weill Cornell and a PhD from the Australian Stem Cell Centre. Historical Lux transactions remain attributed to Lux, rather than being relabeled new Dimension investments.

Zavain Dar is a Dimension founder and managing partner, holding that position since March2022 according to Recursion’s current board biography. Previously a Lux Capital general partner from2014–2022, he invests across biotechnology and software. He engineered machine-learning and AI systems at Discovery Engine and studied symbolic systems and theoretical computer science at Stanford, where he researched in the AI lab. Recursion publishes his board membership sinceSeptember2016; no personal investment check is inferred.

Jefim Gewiet was a managing director of Apeiron Investment Group Ltd. named alongside Julien Höfer in Akili’s2022 original PIPE resale filing. Bionomics’2021 primary Schedule13D lists both as directors; Sensei Biotherapeutics’2024 filing additionally describes Gewiet as a financial advisor and a legal and judicial representative. These dated legal-management affiliations are historical and do not establish current parent employment or a personal Akili cash investment. A July2026 primary filing identifies Sanad Abushala as Apeiron’s sole statutory director. No authenticated original portrait was available in the retrieved current manager sources.

Julien Höfer is a lawyer and real estate and venture investor. His own current Van Houten & Co biography explicitly identifies him as a former managing director of Apeiron Investment Group. Akili’s2022 primary PIPE resale filing names him as a managing director of the legal Apeiron buyer, and earlier Bionomics regulatory filings corroborate his directorship. His own professional biography and issuer Periskop2024 announcement describe international-law-firm work in London, Frankfurt and Berlin and former chairmanship of atai Life Sciences. This is a historical Apeiron appointment; the2026 company filing instead names Sanad Abushala as sole statutory director. His original named own-company portrait is authenticated. No personal Akili check is inferred from beneficial-control wording.

Harrison Koontz’s public professional profile identifies employment at TRCM Fund and education at Virginia Tech. His specific current investment-team title and appointment date are not publicly verified; he is recorded as a source-qualified team member rather than an inferred partner or investment decision-maker.

Matthew Dicken is a serial entrepreneur and investor who founded Strategic Wealth Designers in 2002. His current employer biography identifies board service at Total Return Capital Management, alongside Healthbucks, Nexosome Oncology and Pneuma IP Holdings. He has worked in financial planning since age18, contributed to Kiplinger, written three books and appeared as a financial expert on major US television networks. His verified TRCM role is board service; a current executive title is not independently confirmed.

Sampson Chaim Glassman is identified as an indirect owner in TRCM IM LLC’s June2026 adviser filing through MT Larson Venture Partners LLC and TRCM MM LLC. Primary credit-vehicle offering disclosures separately name him as manager of TRCM Credit Fund segregated portfolios and identify TRCM Capital Advisors LLC as their investment manager. His legal ownership and credit-management roles are distinct from any personal cash investment in the venture portfolio.

Stephen Robert Green is the elected manager of TRCM IM LLC, the investment adviser identified in its June22,2026 primary regulatory filing, which reports his CRD2853952 identity. He is also named as manager of the TRCM fund-class issuers in their June2026 FormD disclosures. The legal manager, general partner and individual investment-fund classes remain distinct entities; these roles do not imply a personal investment in portfolio companies.

Barry McCorkell is named by Perivoli Innovations as an AMAS LLP principal providing advice to its trustees on investment decisions. Related Perivoli primary sources also identify him as a funding-trust trustee and Foundation trustee. These are separate legal entities; this profile records his actual published Innovations advisory affiliation rather than assuming an investment-trust trustee or employee appointment.

James Alexandroff OBE is an investor and philanthropist. Perivoli Innovations names him as an AMAS LLP principal advising its trustees. His own biography confirms this advisory work and describes co-founding Arisaig Partners in1996, gifting his ownership to the Perivoli Trust and establishing the Perivoli Foundation. Foundation and funding-trust affiliations are separate from the Innovations investment vehicle; no automatic private check or employee title is inferred.

Cristyn Girolami is a Layer Global partner whose work centers on talent and organisational growth. Her published mentor biography describes more than25years supporting recruitment, leadership development, compensation and people strategy, including previous chief people officer positions.

Lauren Rakower is Layer Global’s chief compliance officer and general counsel, identified in its August2026 Form ADV. The filing records this executive affiliation beginning inJuly2026.

Arash Rebek leads capital formation and LP relations at Layer Global. His published speaker biography identifies earlier investor-relations roles at Khosla Ventures, Strategic Value Partners and Magnitude Capital, and an initial legal career at Skadden. He holds undergraduate and law degrees from the University of Chicago.

Zachary Kaplan is Layer Global’s co-founder and general partner, as identified in the manager’s August2026 Form ADV. His own launch post also describes his co-founder and partner role.

Anton Levy founded Layer Global after serving as co-president of General Atlantic. He joined General Atlantic in1998 and invested through successive internet, mobile, social and cloud technology cycles. At Layer he focuses on concentrated partnerships with fast-growing technology companies in the AI era.

Raj Airey is a healthcare investor and company builder with international operating experience. Orthox identified him as Additio Investment Group’s investment representative in its February9,2022 financing announcement; the exact Additio job title and current status are not publicly specified. His current primary New Health IG biography describes earlier managing-director work at Pfizer and Baxter, company-building ventures including WizzCare and HealthStart, and experience in healthcare investment and business diligence. It also describes graduate study at London University, executive programs at Harvard Business School and INSEAD, and executive-coaching credentials. Historical corporate roles and prior investment performance are not assigned to Additio’s own funds, and a personal investment is not inferred from the institutional quote.

Banking executive with finance, management and board experience.

Technology entrepreneur and investor with experience developing, acquiring and selling software businesses.

Investor and technology executive with venture-capital and telecommunications experience.

Director with experience in public administration, politics and private-sector governance.

Executive and asset-management professional with experience at Western Bulk, Umoe and Storebrand.

Technology investor with financial-advisory and technology-M&A experience.

Organizational psychologist experienced in strategic and operational human resources.

Finance-trained investor with previous management-consulting experience at EY.

Former Investinor CFO and acting CEO, serving as investment director since 2025.

Technology executive experienced in scaling software businesses, acquisitions, listings and company sales.

Aquaculture and technology investor; previously CFO at Norway Royal Salmon.

Pre-seed investor responsible for Investinor’s Northern Norway co-investment mandate.

Long-serving investor and fund professional who became CFO in 2025.

Law-trained transaction professional with venture-fund, investment-banking and board experience.

Deep-technology and healthcare investor with growth-equity, investment-banking and audit experience.

Former Siemens executive with international strategic-management experience.

Investor with experience in renewable-energy corporate venture capital and Innovation Norway.

Data-science and economics graduate with finance training; joined Investinor in 2025.

Industrial-economics and technology-management graduate with investment-banking and technology-startup experience.

Communications professional specializing in public affairs, media relations, crisis communication and reputation.

Finance graduate with quantitative and asset-management training; joined Investinor in 2026.

Auditor and sustainability professional experienced in development finance, investigations and anti-corruption.

Lawyer experienced in business advice and disputes, with additional organization and management training.

Finance and accounting specialist with prior audit experience at PwC.

Financial-economics graduate with consulting, audit and financial-management experience.

Financial-economics graduate with consulting experience in digitization, innovation and sustainability.

Energy-technology investor with audit, transaction-support and advisory experience.

Venture-fund investor with experience at Innovation Norway and DNB Asset Management.

Software and healthcare investor; previously co-founded and led venture activity at NTNU Technology Transfer.

Financial controller with business-administration training and prior operating-management experience.

Digital-business professional supporting Investinor’s systems and digitization.

Software and deep-technology investor with prior banking and consulting experience.

Seed-fund investor with corporate finance, audit and management experience.

Venture investor focused on healthcare and selected semiconductor and deep-technology companies.

Economics-trained investment professional with prior audit experience and doctoral research at NTNU.

David Friedman, MD is managing director and senior analyst for the healthcare and biotechnology Averill strategy at Montanova Capital, formerly Suvretta Capital Management. He joined the manager in January2020 according to issuer filings. His previous experience includes healthcare analysis at Scopia Capital and biotechnology equity research at Morgan Stanley. He holds an MBA from Harvard Business School, an MD from the University of Pittsburgh School of Medicine and a biology degree from Duke University. His source-published board experience includes Click Therapeutics, Veradermics, Avalyn and Sapphiros; a company board role is not a personal cash ticket.

Andrew Jon Nathanson is general counsel and chief compliance officer of Montanova Capital, formerly Suvretta Capital Management. The current July2026 SEC filing identifies his officer role from March2014 and his legal/compliance responsibility. Issuer beneficial-ownership filings also show him signing for the manager and Averill funds; those signatures do not establish personal investment cash.

Glenn Michael Shepard is chief financial officer of Montanova Capital, formerly Suvretta Capital Management, according to the July2026 SEC FormADV. The filing records his officer status from September2011 and identifies him as a control person. That month-level appointment is not given a guessed day, and no unsupported prior career, education or portrait is assumed.

Kishen Mehta is chief investment officer of the Averill and Averill Madison healthcare strategies at Montanova Capital, formerly Suvretta Capital Management. His earlier roles include strategic advising for Biohaven, healthcare portfolio management at Surveyor Capital/Citadel, investment analysis at Adage Capital and Apothecary Capital, and life-science M&A at Evercore. He graduated in finance and accounting from NYU Stern in2007. His published work includes neuroscience and biotechnology investments; his separate VentureHaven founder affiliation supplies the authentic named portrait and is not treated as the same fund manager.

Aaron Cowen founded the investment manager historically called Suvretta Capital Management in2011, now branded Montanova Capital. He is chief executive officer in the July2026 SEC filing and chief investment officer of the generalist long/short Suvretta strategy on the current website. His earlier investment career includes Soros and serving as CIO for Steve Cohen, as described by the primary2026 Liquidity Summit. His authentic conference portrait is source-published; beneficial-control reporting is not a personal cash investment.

Lourens D. Verweij is a co-founder and founding partner of Additio Investment Group, an international syndicate supporting healthcare and life-sciences entrepreneurs. Primary professional contributor material describes him as an investor, company builder and board advisor, and as chairman of LSHAccess Foundation. His contributed investment guidance emphasizes technology milestones, clinical evidence and how financing reduces development risk, rather than treating investigational products as already validated. The2022 venture.ch advisory-council booklet independently names his Additio founding-partner role. Wider current corporate appointments, education and any personal investment amounts require separate primary verification; institutional Additio checks are not assigned to him personally.

Ian Jepson joined Cytotrait as a non-executive director in September 2026. He spent 35 years at Syngenta and predecessor businesses, with leadership roles in seeds research, genome editing, trait discovery and crop breeding. He holds a University of Birmingham PhD in genetics.

Anil Day co-founded Cytotrait and advises its science. A University of Manchester reader, he researches chloroplast biology and genetic engineering for crop improvement and co-invented the MOSS platform with Junwei Ji.

Tim Brears is executive chair of Cytotrait. He has led biotechnology companies including Evonetix, Xention and Gendaq and worked in business development at Ciba-Geigy/Novartis. He holds a Cambridge PhD in plant molecular biology and a Duke MBA.

Junwei Ji co-founded Cytotrait and is its executive director. His University of Manchester PhD research on precise chloroplast DNA mutagenesis contributed to the MOSS platform. He led the company’s ICURe commercialisation programme and previously worked in hybrid maize breeding.

Cassie Doherty is a Northern Gritstone investment director with experience in life sciences company building, diligence, strategy, transactions and governance. IVFmicro publishes her in its board section, and Companies House lists her as Cassandra Clare Doherty.

Enrico Sangiorgio is executive chair of IVFmicro. His experience spans healthcare executive leadership, business development and scaling early-stage ventures, including leading Sensiia as CEO and securing Series C investment.

Helen Parris is IVFmicro’s chief executive officer. She holds a PhD in reproductive medicine and has led commercial strategy, market access and product launches in regulated life sciences markets, including senior positions at Arecor Therapeutics, Albireo Pharma and Gilead Sciences.

Helen Picton co-founded IVFmicro and is its chief scientific officer. A University of Leeds professor, she specialises in female reproductive biology, embryology, fertility preservation and assisted reproduction. She founded the university’s Reproduction and Early Development research group and is scientific director of Leeds Fertility.

Virginia Pensabene co-founded IVFmicro and is its chief technology officer. A University of Leeds associate professor, she researches microfluidics, biomedical engineering and organ-on-chip technologies. She holds a PhD in Humanoid Technologies from the University of Genoa and the Italian Institute of Technology, and previously founded medical startup WinMedical.

Mario Frendo formerly served as a statutory director of Apeiron Investment Group Ltd., signing primary2025 and May2026 public regulatory filings. His own2026 professional announcement states that his Apeiron tenure ended and that he moved to Deriv as Senior Legal Counsel. The exact departure day is unpublished in retrieved sources, so structured dates remain unknown; the role is historical. No current Apeiron employment or personal company investment is inferred. No authenticated original portrait was available in the retrieved primary profile sources.

Sanad Abushala is Apeiron Investment Group Ltd.’s sole statutory director and Head of Treasury, explicitly identified in its July17,2026 primary Schedule13D filing. His principal professional address is in Birkirkara, Malta, and the filing identifies Croatian citizenship. These are source-confirmed legal and treasury positions; no education, earlier employers, founding role or personal investment is inferred. No authenticated original portrait was available in the current own manager sources retrieved.

Shane Wilson invests at Citta Capital in early-stage B2B AI, deep technology and robotics. His 2026 podcast interview identifies him as Managing Partner, while Citta’s own public event announcements describe him as Venture Partner. His background includes startup go-to-market, workforce technology, commercialization, enterprise strategy and venture investing. He helps founders connect technical products with customer value, pricing and defensible businesses.

Fred Sun is a member of Citta Capital’s publicly identified investment team. Current firm communications tag his own Fred S. profile alongside Jim Mao and Shane Wilson in discussions of agentic AI, enterprise adoption, defensibility and portfolio companies. His current exact operating title is not published in those primary communications; older investment-directory titles are not treated as a confirmed current promotion.

Jim Mao is Founding and Managing Partner of Citta Capital and Managing Member of Citta Capital Management, LLC. He founded the venture firm in 2020 to back early-growth technology companies across AI, enterprise software, cloud and healthcare technology. He previously was a Partner at WestSummit Capital, where he led investing in enterprise, cloud, big data, AI, robotics and digital media, following executive roles in startup and established technology businesses. His current regulatory filing confirms his Managing Member role; his earlier director biographies describe five co-authored US patents and education at the University of Southern California.

Named in Pacertool’s public company LinkedIn employee list. Precise current executive title is not independently confirmed.

Cardiac electrophysiologist specializing in ablations and cardiac-device implantation, named in the issuer’s 2022 advisory board.

Cardiology professor researching devices and heart failure, named in the issuer’s 2022 scientific advisory board.

Cardiologist researching device therapy for arrhythmias and heart failure, named in the issuer’s 2022 advisory board.

Cardiology professor and clinical-trial investigator, published in the issuer’s 2022 scientific advisory board announcement.

Medical-device executive named CEO in Pacertool’s October 2022 release. Augere Medical now publishes him as its CEO; no exact Pacertool departure date is established.

Cardiologist and founder of Pacertool, independently identified by Oslo University Hospital and Simula. Executive title is from the dated issuer release, not independently confirmed as current.

Pluvia announced his transition from CEO to board member on August 24, 2026.

Healthcare investor with international asset-management and equity-analysis experience at NBIM and UBS.

Biomedicine researcher supporting protein purification, compound screening and blood-sample processing.

Nanoscience-trained researcher conducting phenylalanine analysis, enzyme-activity assays and in-vitro experiments.

Molecular biologist working on mouse-colony maintenance, genotyping and in-vivo experiments.

Biomedicine researcher planning and conducting in-vivo experiments and transgenic mouse studies.

Pharmacist and cell-biology researcher overseeing cell culture and preclinical development.

University of Bergen biochemistry professor researching protein structure, stability and pharmacological chaperones.

Rare-disease biotechnology executive with clinical, regulatory and company-building experience; appointed CEO August 24, 2026.

Ms. Lawrence has served as trustee of the Delaware Funds by Macquarie, as a director of its New York and Australian Stock Exchange-Listed close-end funds, DEW/VCF/DDF/VMM/VFL/IVH, and on its Audit and Investments Committees since 2021. She has served as a trustee of its legacy Ivy and Waddell and Reed Mutual Funds Complex Trust, and on its Governance Committee, since 2019. Ms. Lawrence was the Executive Vice President and Chief Financial Officer of Children’s Mercy Hospital, a comprehensive pediatric medical center in Kansas City, Missouri, from 2005 to 2016 and the Executive Vice President and Chief Administrative Officer of Children’s Mercy Hospital from 2016 to February 2019. She was Senior Vice President and Treasurer of Midwest Research Institute, an independent, non-profit, contract research organization, located in Kansas City, Missouri, and subsequently its Chief Financial Officer. Ms. Lawrence spent twenty-six years in professional or management positions in the architecture, real estate, investment banking, financial services, packaging, and medical research industries. Ms. Lawrence also serves as a member of the board of directors of Evergy, Inc., a publicly traded company that provides clean, safe and reliable energy to 1.6 million customers in Kansas and Missouri, where she serves as chair of the Nominating, Governance, and Corporate Responsibility Committee, and as a member of the Compensation and Leadership Development Committee. Ms. Lawrence serves on the board of directors of American Shared Hospital Services, a publicly traded company that provides radiosurgical and radiation therapy equipment and services, based in San Francisco, California, where she serves as chair of the Audit Committee and as a member of the Nominating and Corporate Governance Committee. Additionally, she serves on the board, as chair of the Risk Oversight Committee, and on the Governance, Compliance, and Talent and Compensation Committees, of Recology, a large, private, Employee Stock Ownership Plan company that provides collection and disposal of municipal solid waste, recycling, and organic/compost to commercial and residential customers in California, Oregon, and Washington. Ms. Lawrence has been the chair of the board of directors of the Heartland Chapter of the National Association of Corporate Directors (NACD), was named one of its Directorship 100, and an NACD board leadership fellow. She serves on the boards of directors of various charitable, non-profit and civic organizations, including the Hall Family Foundation, the Nelson-Atkins Museum of Art, and Women Corporate Directors. Ms. Lawrence is a graduate of Vassar College, where she received her Bachelor of Arts in psychology. She also received a Master of Architecture from the Massachusetts Institute of Technology and a Master in Business Administration from Harvard Business School. We believe Ms. Lawrence is qualified to serve as a member of our Board because of her work experience, financial background, academic background and service on corporate and charitable boards.

Mark Capone has served as a member of our Board of Directors since July 2026 and is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors. Previously, he served as Chief Executive Officer of Myriad Genetics, where he led the company’s transformation into a focused precision medicine organization, expanding its molecular diagnostics portfolio and strengthening its commercial execution. Prior to serving as CEO, he held several senior leadership roles at Myriad during his 17-year tenure, including President and Chief Operating Officer. Earlier in his career, Mr. Capone held leadership positions at Eli Lilly and other healthcare organizations, building deep expertise in pharmaceutical commercialization, strategic planning, and business development. He currently serves as a non-executive director at Mesa Laboratories, where he is Chair of the Compensation Committee, and at Owlstone Medical, where he serves on the Compensation Committee. Mr. Capone received a Master of Science in Chemical Engineering and a Master of Science in Management from the Massachusetts Institute of Technology, and a Bachelor of Science in Chemical Engineering from Pennsylvania State University. We believe that Mr. Capone’s qualifications to serve on our Board of Directors include his extensive experience commercializing complex diagnostic products, his deep understanding of reimbursement and payer environments, and his proven ability to scale innovative diagnostic platforms and build high-performing commercial organizations.

Mansoor Raza Mirza, M.D. has served as a member of our Board since December 2014. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet — the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr. Mirza is Chairman of the European Network of Gynaecological Oncological Trial groups, or ENGOT. Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. Dr. Mirza is the author of several phase 1, 2 and 3 studies. Several of those studies led to FDA and European Medicines Agency registrations. He serves on several Independent Data Safety Monitoring Committees of international studies. He is an invited speaker at several international conferences, such as “Meet the Professor” at American Society of Clinical Oncology and “Presidential Symposium” at European Society for Medical Oncology. He is the author of global consensus guidelines for the management of ovarian cancer and of European guidelines for the management of several gynecological malignancies. His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, faculty member of the European Society of Medical Oncology and of ESGO. He also serves on the board of directors of Karyopharm Therapeutics Inc., a public pharmaceutical company and has served as a clinical consultant to Karyopharm Therapeutics Inc. since 2010. He has multiple publications in high-impact journals, including several publications in the New England Journal of Medicine and the Lancet. He holds an M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark. We believe Dr. Mirza’s qualifications to serve on our board include his expertise in gynecologic cancers, and his knowledge of our company and its business through service on our board since December 2014.

Jacky Cheung is Head of Finance of CLSA Capital Partners in current own public management pages. He provides financial and governance oversight of the affiliate’s strategies and previously worked in finance at CITIC Capital. He is recorded with his exact finance identity, distinct from the singer and other namesakes.

Kim Kamdar, Ph.D. has served as a member of our Board since November 2011, and as Board Chair since May 2023. Dr. Kamdar is currently a Partner at Domain Associates, LLC, a venture capital firm, where she has worked since 2005. Prior to Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital, as well as a research director at Novartis International AG. Dr. Kamdar is currently Chair of the Board of Directors of Seraphina Therapeutics and Truvian Sciences, Inc. and serves on the board of directors of EvoFem Biosciences, Inc. (Nasdaq: EVFM), Obalon Therapeutics, Inc. (Nasdaq: OBLN) and Singular Genomics Systems (Nasdaq: OMIC). Dr. Kamdar currently serves on the board of several private companies including: Epic Sciences, Inc., Alume Biosciences and Pleno, Inc. Dr.Kamdar serves as an advisory board member of Dr. Eric Topol’s NIH supported Clinical and Translational ScienceAward for Scripps Medicine and is also on the nonprofit board for Access Youth Academy, an organization that is transforming the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash. Dr. Kamdar received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University. We believe Dr. Kamdar is qualified to serve on our Board of Directors based on her extensive experience working and serving on the boards of directors of life sciences companies and her experience working in the venture capital industry and her knowledge of our company and its business through service on our board since November 2011.

Derek Hung leads transaction management at the affiliated CITIC Securities CLSA Capital Partners business, which he joined in2021. Its own biography describes his legal and investment experience at China-ASEAN Fund, CCB International and Clifford Chance and qualifications in England and Wales, New South Wales and Hong Kong.

Amy Jia is Director of Credit Business in CLSA’s public alternative-investment management page. The affiliate’s own biography additionally identifies her as Head of Healthcare Investment Division, CLSA China Growth Fund, following Goldstone healthcare experience. This unit-specific role is not a direct claim that the broad CLSA platform subscribed to each affiliate fund.

Joshua Phillips has served as a member of our Board since January 2011. Since 2008, Mr. Phillips has been a Managing Partner of Catalyst Health Ventures (CHV), a venture capital fund investing in medical technology and life science companies.Mr. Phillips led Catalyst’s investments in Novazyme Pharmaceuticals, Inc. (acquired by Genzyme Corp.), BioTrove, Inc. (acquired by Life Technologies Corp.), Biocius Life Sciences, Inc. (acquired by Agilent Technologies, Inc.), Vortex Medical, Inc. (acquired by AngioDynamics), Allegro Diagnostics, Inc. (acquired by Veracyte, Inc.), SevenOaksBiosciences (acquired by Medline Industries, Inc.), Pavilion Medical Innovations and Cruzar Medsystems, in addition to our company. Prior to joining Catalyst, Mr. Phillips was the Managing Partner of Catalyst Health and Technology Partners prior to CHV, where he led investments in Novazyme Pharmaceuticals, Inc. (NASDAQ:SNY), BioTrove, Inc. (NYSE:TMO) and Biocius Life Sciences, Inc. (NYSE:A). Mr. Phillips is a director at several privately held companies, including Conformal Medical, Inc., Brixton Biosciences, Inc., Saphena Medical, Inc., and Cruzar Medsystems, Inc. Mr. Phillips holds an M.B.A. from the Harvard Business School and a B.E. in Electrical Engineering and Mathematics from Vanderbilt University. We believe that Mr. Phillips’ qualifications to serve on our board include his extensive experience in the life science, diagnostics and medical device markets, his extensive experience serving on boards as Chairman, Lead Director, Audit & Compensation Committee Chair and Member and his knowledge of our company and its business through service on our board since January 2011.

Deborah Feng is an alternative-investment division leader. The CLSA platform page calls her Head of Strategy and Business Development and Executive Director, Private Equity; the affiliate’s own biography calls her Deputy Head of CITICS CLSA Capital Partners. Both published titles are retained rather than inferring an appointment date. Her previous work includes Goldstone healthcare investment and Zhong De Securities.

Baifeng Hu is a CITIC CLSA Management Committee member and leads its separately named alternative-investment business, CITIC Securities CLSA Capital Partners. His own biography describes prior Goldstone and CDB Capital experience and investments in healthcare, technology and advanced manufacturing. His affiliate leadership is qualified within the broader CLSA platform.

Dr. Barlow has served as Chief Executive Officer of Jane Barlow & Associates, LLC, a consulting firm focused on value-based health care services, since January 2017, and Executive Vice President and Chief Clinical Officer at Real Endpoints, a data, analytics, and advisory firm, since January 2017. She currently serves on the board of directors of ContraFect Corp., a publicly traded biotechnology company, and Viracta Therapeutics, Inc., a publicly traded precision oncology company. Dr. Barlow also serves on the board of directors of Point Health, a healthcare navigation platform, the advisory board of Refactor Health, and the Biotech Advisory Board of Pictet Asset Management, an asset management firm. Prior to her current roles, Dr. Barlow was Associate Chief Medical Officer at CVS Health and Chief Medical Officer of CVS Health’s Government Services arm where she successfully implemented industry-leading clinical strategies supporting drug purchasing, distribution, and utilization management. Formerly, she served as Vice President of Clinical Innovation at Medco Health Solutions, leading the adoption of cutting-edge therapeutic programs through all aspects of pharmacy. Dr. Barlow previously served on the board of directors of Momenta Pharmaceuticals, Inc., (prior to and during its sale to Johnson and Johnson), Therapeutics MD Inc., and SilverScript Insurance Company. Dr. Barlow received her medical degree from Creighton University School of Medicine and subsequently completed her residency in occupational and environmental medicine at The Johns Hopkins University, where she also earned her M.P.H. Additionally, she holds an M.B.A. from the University of Alabama. She is board-certified in occupational medicine and a fellow of the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. She is a diplomat of the American College of Physician Executives and a member of the American Medical Association.

Ruan van Vuuren is a Cayman Islands board member and fund director at International Management Services. The company biography identifies chartered-accountancy, alternative-investment and governance qualifications, earlier Cayman Islands Monetary Authority work and PwC audit experience. Alyeska’s March 2026 Form ADV names him in governance of its master and two feeder vehicles. This is an external governance affiliation, distinct from the same-name supply-chain consultant and from employment or personal investing at the manager.

Edward Park leads CLSA institutional equities and is Deputy CEO of CITIC Securities International in its September2025 own release. He joined CLSA in1998 and has held sales, trading and execution leadership across Asian offices. His authentic portrait comes from the Shanghai Stock Exchange’s named2022 conference programme, with his current title independently sourced from the firm.

Yang Yu, also rendered Yu Yang, is the head of investment banking at CITIC Securities International and a director of CLSA Limited and other named subsidiaries in own statutory filings. His role is qualified by legal unit and is not an assumed private-equity portfolio attribution.

Ebony Myles-Berry is a Cayman Islands fund director at International Management Services. Her own biography describes earlier Maples Fiduciary Services and regulatory/administrative work and qualifications in finance and investment-fund governance. Alyeska’s March 2026 Form ADV names her on the governance lists of its master and two feeder vehicles. She is recorded as an external fund director, without inferring employment at Alyeska or personal portfolio allocations.

Gregory C. Critchfield, M.D., M.S. served as our Chairman, President and Chief Executive Officer from November 2011 through May 2023. Dr. Critchfield brings decades of experience in the diagnostics industry, including a proven track record of successfully launching diagnostics products and significantly growing revenues for leading diagnostics companies. Previously, Dr. Critchfield was President of Myriad Genetic Laboratories, a wholly-owned subsidiary of Myriad Genetics, Inc., a molecular diagnostics company, from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Dr. Critchfield’s role at Myriad, he served as Senior Vice President, Chief Medical and Science Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Prior to Quest Diagnostics, Dr. Critchfield was the Director of Clinical Pathology at Intermountain Health Care. Dr. Critchfield has served on the boards of Saladax Biomedical Inc., BioTrove Inc., Biocius Life Sciences, Inc., Integrated Diagnostics, Inc., Nodality, Inc., Metamark Genetics, Inc., Lantos Technologies and Condor Therapeutics, Inc., and currently serves as a director of Epic Sciences. He also served as both a reviewer and an NIH Study Section Chair for biomedical computing grants over a period of time encompassing fifteen years. He holds a B.S. in Microbiology from Brigham Young University, an M.S. in Biophysical Sciences from the University of Minnesota and an M.D. from the University of Utah College of Medicine. We believe that Dr. Critchfield’s perspective and experience as our President and Chief Executive Officer, as well as his depth of experience in the diagnostics industry, provide him with the qualifications and skills to serve on our board of directors.

Jianqiang Xu, also known as James Xu, is Co-Chief Executive Officer of CITIC CLSA from February2025 according to own2025/2026 disclosures. He oversees multiple business lines including equity derivatives, wealth and asset management after joining CITIC Securities in2005. His corporate platform responsibilities are distinct from the separate managers’ fund corpus.

Christopher (Chris) Bowring is a Cayman Islands professional director at International Management Services, whose own biography identifies accounting, governance and trust qualifications and prior fiduciary leadership. Alyeska’s March 2026 Form ADV explicitly names him in the governance of Alyeska Master Fund, Aleutian Fund and Alyeska Fund. This external fund-board affiliation does not make him an Alyeska portfolio manager, employee or company investor.

Jennifer Zibuda has over 15 years of experience in investor relations, corporate communications, and capital markets across the biotechnology and healthcare sectors. As Head of Investor Relations for Sera, she leads investor engagement, oversees quarterly earnings communications, and partners with executive leadership to support the company’s strategic and financial messaging. Jennifer works closely with finance and legal teams to ensure consistent and compliant disclosures, and collaborates cross-functionally on communications related to partnerships, business development, and corporate growth initiatives. Prior to joining Sera, Jennifer served as Senior Director of Investor Relations at Vaxcyte where she helped evolve the the company’s shareholder base as it advanced into late-stage clinical development. She previously held investor relations and corporate communications roles at Prothena Biosciences, Portola Pharmaceuticals, and Alkermes. Jennifer holds a Master of Arts in Corporate Communication and Public Relations from Sacred Heart University and a Bachelor of Arts in Psychology from the University of Connecticut.

Benliang Shi, also rendered Shi Benliang, is a director of CITIC Securities International and CLSA subsidiaries in own statutory disclosures. He joined CITIC Securities in2000 and has held finance and wealth-management leadership. This statutory group role does not imply a personally attributed CLSA venture check.

Brent Metrick Cunningham is Alyeska Investment Group’s chief compliance officer. The March 23, 2026 Form ADV names him with the title acquired in February 2018 at month precision; the manager’s August 4, 2026 SEC N-PX filing independently confirms his current role. His public professional profile identifies Alyeska and California Western School of Law. Portfolio reporting and regulatory signatures are not evidence of personal equity checks.

Chunbo Li, also rendered Li Chunbo, leads CITIC CLSA and its parent CITIC Securities International. Own group publications identify him as chairman and CEO and a director of CLSA Limited and CLSA B.V. His group governance capacity is distinguished from personally executing the platform’s historical investments.

Adrienne Lugo has over 20 years of leadership experience in women’s health and molecular diagnostics, with a strong track record of building high-performing teams, expanding market access, and partnering with physicians and health systems to deliver innovative testing solutions. Adrienne has served in commercial leadership roles at BillionToOne and Bayer Healthcare, where she was instrumental in driving growth and advancing adoption of novel diagnostic technologies. As Head of Sales and Strategic Accounts, Adrienne leads the company’s commercial strategy and key partnerships to support continued growth and broader adoption of Sera’s technology. Her deep expertise and strategic approach will be critical as the company expands its impact on maternal and fetal health. Adrienne began her career in healthcare sales and has held roles of increasing responsibility across the diagnostics and life sciences sectors, consistently delivering strong results in competitive and evolving markets. Adrienne is the proud mother of three children (triplets) and resides in Tampa with her family and rescue dog. She is driven by a strong sense of purpose, which aligns closely with Sera’s mission to improve pregnancy outcomes for mothers and babies.

Jason Aaron Bragg is Alyeska Investment Group’s chief financial officer, named in its March 2026 Form ADV and May 2026 SEC signatures. The ADV records the CFO role from February 2008, at month precision, and a trustee role in Alyeska Partners Trust from March 2024. He is also a named director/governance participant for the manager’s master and feeder vehicles. His fund or trust roles are distinguished from a personal portfolio check; no exact appointment day is inferred.

Liana Burns has nearly 15 years of experience in payer, health system, and non-profit environments where she focused on building and deploying population health strategies. As Head of Payer, Government & Strategic Partnerships she is responsible for leading Sera’s strategic partner engagement strategy to drive adoption and coverage. She partners with stakeholders to align frameworks that improve maternal health outcomes with a strong emphasis on value-based adoption, health equity, and population health impact. Before joining Sera, Liana was deeply engaged in Elevance Health’s whole health strategy during its inception and operationalization in Medicaid. She furthered the company’s maternal health strategy, specifically expanding access to doula care across the country. Additionally, she designed social care and health equity strategies across a nationwide footprint, integrating a community-based approach to the business. Liana began her career in patient advocacy, working both at non-profits and community hospitals in the DC, Maryland, and Virginia area building population health interventions, patient engagement strategies, and participating in advocacy coalitions. Liana holds a Master of Health Administration from the Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Public Health from George Washington University. She lives in Brooklyn, NY and spends her free time training for races and hiking with her blue heeler, Remy.

Anand Christopher Parekh founded Alyeska Investment Group in 2008 and is its chief executive officer, verified by the March 2026 SEC Form ADV and current transaction filings. The University of Michigan identifies degrees in English and mathematics and earlier work at Deutsche Bank and Citadel, where he headed equities. The ADV names him in governance of Alyeska Master Fund and its feeder vehicles. Deemed beneficial ownership through management authority does not establish a personal company investment. He is distinct from the same-name physician/public-health leader at the Bipartisan Policy Center.

Cassondra joins Sera with more than 15 years of experience in healthcare, diagnostics, and commercial leadership, bringing a proven track record of driving growth, adoption, and innovation across women’s health and molecular diagnostics. Most recently, she served as Director of Marketing for Molecular Diagnostics at Waters Corporation via acquisition from Becton, Dickinson and Company, where she led commercialization strategies for women’s health and infectious disease portfolios. Throughout her career, Cassondra has successfully launched 14 products and most recently led clinician and consumer activation efforts to expand access to cervical cancer screening through innovative care models, including at home testing solutions. She is known for translating complex clinical science into compelling customer value propositions that drive provider adoption, behavior change, and business growth. Her expertise spans commercialization, market development, key opinion leader engagement, omnichannel marketing, and cross functional leadership. Outside of work, Cassondra enjoys competing in bowling tournaments, cooking with friends and family, and exploring new restaurants and culinary experiences. She believes many of life’s greatest connections are built around shared experiences, whether in the workplace, on the lanes, or around the dinner table. Cassondra is excited to bring her passion for women’s health, commercialization, and team development to Sera as the company continues its mission to improve outcomes for mothers and babies.

Nikki Martin has over 25 years of experience with hands-on successes in building and leading top-performing teams, overcoming technical challenges, and achieving desired outcomes in the laboratory, CRO, IVD, medical device, and biopharmaceutical manufacturing sectors in US and international settings. Nikki has served as our Vice President of Quality/Regulatory and Privacy Officer since May 2020. In her role as Vice President of Quality/Regulatory and Privacy Officer, she oversees all quality assurance and regulatory activities within Sera, including the CAP/CLIA laboratory and regulated activities throughout the company. She works very closely with the heads of all departments to ensure the highest quality results delivery and compliance with applicable regulations. Nikki is also our Executive People Sponsor overseeing our Human Resources department. She holds a number of certifications in quality, regulatory, compliance, and human resources from the respective professional societies. Nikki began her career as a cytogenetics technologist before transitioning to Quality and then held various roles with increasing responsibility in organizations of various size and complexity. Nikki occasionally serves as an ad-hoc consultant for venture capital firms and small start-up clients. She holds an M.S. in Quality Assurance and Manufacturing from California State University, and a B.S. in Biochemistry, and a minor in Genetics from North Carolina State University.

Angie Fox has over 25 years of experience in clinical research in academia and industry, including over 12 years in the medical diagnostics industry. Angie joined Sera in November 2011 as the Director of Clinical Operations and served as Associate Vice President of Clinical Operations from 2017 to 2022. Angie has been responsible for developing and overseeing the Clinical Operations team and clinical quality management for several large and small multicenter-sponsored studies, as well as overseeing investigator-initiated projects with Sera. Before joining Sera, Angie was an Associate Director in Clinical Development and Medical Affairs at Pfizer in rare disease, and a Genetic Counselor and research coordinator in biochemical genetics and inherited metabolic disease focusing on lysosomal storage disorders at the University of Washington. Angie began her career in the laboratory, including a two-year technical predoctoral fellowship in the Laboratory of Molecular Biology, Section of Developmental Genetics at the National Cancer Institute. Angie holds a M.S. in Genetics and Biophysics from the University of Colorado Denver and a B.S. in Molecular Biology. She has been a Diplomate of the American Board of Genetic Counseling since 2002 and is a Certified Genetic Counselor licensed in the state of Washington.

Rob Harrison serves as an Information Technology Advisor to Sera Prognostics. During his tenure with the Company, including service as Chief Information Officer, he helped guide Sera’s technology strategy, infrastructure development, and information management initiatives. With more than 30 years of executive technology leadership experience, Rob previously served as Chief Information Officer at Myriad Genetics, where he played a key role in building the technology infrastructure that supported the company’s growth into a global precision medicine leader. He remains active in the technology community through organizations including the Utah Technology Council and AIM Utah CIO Council.

Dr. Paul Kearney serves as a Data Science Advisor to Sera Prognostics. During his tenure with the Company, including service as Chief Data Officer, he helped shape Sera’s data strategy and evidence-generation efforts. A recognized leader at the intersection of healthcare, data science, and innovation, Dr. Kearney has co-founded multiple biotechnology companies focused on oncology, pregnancy health, and food allergy, and has extensive experience in clinical research, bioinformatics, and product development. He has authored more than 100 scientific publications, is the inventor on more than 12 patents, and holds a Ph.D. from the University of Toronto.

Austin Aerts serves as a strategic advisor to Sera Prognostics, providing guidance on key initiatives and supporting operational continuity. Since joining the Company in 2017, he held multiple finance leadership roles, including Chief Financial Officer, and played a pivotal role in Sera’s successful initial public offering and transition to the public markets. Prior to Sera, he worked at Myriad Genetics and Ernst & Young LLP. Austin holds a Master of Accounting from the University of Utah and is a Certified Public Accountant licensed in the State of Utah.

Dr. Michael Foley is considered a national authority on Critical Care Medicine in Obstetrics. Before joining Sera, Dr. Foley practiced Maternal-Fetal Medicine in private practice for more than 20 years and recently retired from a 10-year role as Chairman of Obstetrics and Gynecology at the University of Arizona College of Medicine Phoenix/Banner University Medicine. He was the President of the Society for Maternal-Fetal Medicine (2008) and the recipient of the Society for Maternal-Fetal Medicine Lifetime Achievement Award (2013). He has also served as a Board Examiner in the subspecialty of Maternal-Fetal Medicine. Dr. Foley received his medical degree from Chicago Medical School in 1984. His Obstetrics and Gynecology residency and Maternal-Fetal Medicine fellowship were completed at The Ohio State University Hospital in 1988 and 1990, respectively. In addition to a long list of professional clinical accomplishments, Dr. Foley has a heart for giving back to the medical community. He is a founding instructor and faculty member for the Dan O’Keeffe, M.D. Society for Maternal Fetal Medicine’s Academy for Leadership and Development which is in its eighth year of training hundreds of medical leaders and professionals. Dr. Foley is also generous with his expertise, becoming an award-winning teacher and author. He is the Lead Editor of Obstetric Intensive Care: A Practical Manual (McGraw-Hill) which is currently in its fifth edition (2018). He is also a co-editor for Critical Care Obstetrics-Fifth and Sixth Editions (Wiley-Blackstone). We’re fortunate to access his medical leadership, a clinical prowess that is only matched by a passion for helping others.

Douglas Fisher, M.D. currently serves as a Strategic Advisor to Sera. He previously served as our Chief Business Officer from January 2015 to January 2022. Dr. Fisher served as a member of our board of directors from November 2011 to January of 2015 while he was a Partner a InterWest Partners LLC, a venture capital firm. Dr. Fisher led our Series A financing from InterWest in 2011. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm. He currently is a Partner at Revelation Partners, a healthcare focused venture firm. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.

Benjamin G. Jackson has served as our General Counsel since April 2021. From February 2006 to March 2021, Mr. Jackson was employed by Myriad Genetics, most recently serving as Executive Vice President, General Counsel and Secretary. Mr. Jackson held various positions in Myriad’s Legal Department, including serving as associate general counsel prior to assuming the role of general counsel. Mr. Jackson received his J.D. from the J. Reuben Clark Law School at Brigham Young University and a B.S. in microbiology, immunology and molecular genetics from the University of California, Los Angeles.

John J. Boniface, Ph.D. has served as our Chief Scientific Officer since November 2011. Prior to that, Dr. Boniface briefly served as our Vice President of Research from September 2011 to November 2011. In his role as Chief Scientific Officer, Dr. Boniface is involved with our product development. Dr. Boniface previously served as scientist and program director for multiple biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development, including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals and Eos Biotechnology. Dr. Boniface holds a Ph.D. in Biochemistry from Albany Medical College and a B.S. in Biochemistry from the University of Massachusetts, Amherst. Dr. Boniface was a post-doctoral scholar in the laboratory of Dr. Mark Davis, Department of Microbiology and Immunology, Stanford University School of Medicine.

Scott Gleason is a diagnostics, life sciences, and healthcare executive with approximately 25 years of experience in finance, investor relations, corporate strategy, corporate communications, and equity research. Prior to joining the Company, he served as Vice President, Investor Relations and Treasury, of Neogen Corporation, an international food safety company. Before his role at Neogen, he served as the Chief Financial Officer of NX Prenatal, Inc., a prenatal diagnostic company, and LarmorBio, Inc., a Boston-based life sciences and clinical diagnostics startup. Prior to that, Mr. Gleason served as Interim Chief Financial Officer, Senior Vice President, Investor Relations and Corporate Communications of OraSure Technologies, Inc., a developer and manufacturer of diagnostic tests and sample collection solutions. Before joining OraSure, Mr. Gleason served as Senior Vice President, Investor Relations and Corporate Strategy for Myriad Genetics, Inc., a specialty diagnostics laboratory. Prior to Myriad Genetics, Mr. Gleason was a senior publishing analyst at Stephens Inc., where he covered the life science tools and diagnostics industry. Earlier in his career, he served as a United States Air Force aircraft maintenance officer. Mr. Gleason received a Bachelor of Science degree in Economics from the United States Air Force Academy in Colorado Springs, Colorado.

Dr. Tiffany Inglis is a board-certified Obstetrician Gynecologist with over 25 years of experience in direct care and the healthcare payer industry. In her role as Chief Medical Officer at Sera, she oversees clinical strategy, connecting research and development, clinical operations, data science, and commercial strategy. Her focus is ensuring that Sera’s products are backed by robust evidence and clear clinical value. Dr. Inglis provides enterprise-wide clinical leadership to align medical vision with corporate mission. Before joining Sera, Dr. Inglis was the Chief Medical Officer at Carelon Health, where she led evidence-based intervention programs supporting patient care navigation offerings. Prior to her time at Carelon, she served at Elevance Health, where she led a Commercial Health Plan, supported value-based care programs, and process improvement delivering population health initiatives. She specialized in using data to develop clinical program enhancements across lines of business and specialty areas. During her tenure, she helped redesign the Women and Children’s Health portfolio, build strategic solutions for multiple subspecialty areas, and led external partnerships focused on quality and value. Dr. Inglis earned her medical degree from the Medical College of Ohio. She holds a Bachelor of Science degree in Zoology, magna cum laude, from The Ohio State University, where she was also a collegiate volleyball player. In her free time, she enjoys spending time with her husband and two children.